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Abstract 
 
The Human Immunodeficiency Virus type 1 (HIV-1) integrase is an essential 
enzyme required for viral replication. Integrase forms part of an ensemble of 
proteins known as the preintegration complex and functions by a two-step 
process. Firstly, the cleaving of the 3’ ends of the viral cDNA genome, known as 
3’-end processing. The second step is the insertion of these ends into host DNA 
by esterification, known as strand transfer. There is no human homologue to 
integrase which makes it an ideal drug target. However, the strand transfer 
inhibitor raltegravir is currently the only antiretroviral treatment available that 
inhibits integrase. The aims of this study were two-fold: firstly to characterise a 
cohort of South African patients so as to determine the viability of introducing 
raltegravir as a new treatment option, and secondly, to set up high-throughput 
integrase inhibitor screening assays (testing integrase enzymatic functionality). 
An HIV-1 subtype C specific RT-PCR and PCR assay was established for integrase 
genotyping using 51 integrase inhibitor-naïve patient plasma samples and 22 
antiretroviral drug-naive primary viral isolates from South Africa. Seventy-one of 
the 73 samples were classified as HIV-1 subtype C and two samples were unique 
AC and CG recombinants in integrase. Amino acid sequence analysis revealed 
there were no primary mutations (Y143R/C/H, Q148H/R/K, and N155H/S) 
associated with reduced susceptibility to the integrase inhibitor raltegravir. 
However, one sample had the T97A mutation, three samples had the E157Q and 
V165I mutations, and the majority of samples contained the polymorphic 
mutation, V72I. The expected finding of no major integrase mutations conferring 
resistance to integrase inhibitors suggests that this new antiretroviral drug class 
will be effective in our region where HIV-1 subtype C predominates. However, 
the impact of E157Q and other naturally occurring polymorphisms warrants 
further phenotypic investigation. The integrase sequence of viral isolate, FV3, 
was closest to the consensus sequence, and thus chosen for preintegration 
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complex isolation for use in strand transfer assays. Isolation of preintegration 
complexes following FV3 infections of several cell lines was unsuccessful as 
determined by western blot analysis. Subsequently, the focus was changed to 
isolation of HIV-1 subtype B recombinant integrase and its functional evaluation. 
Expression of native integrase (INwt) and soluble integrase (INsol) was induced in E. 
coli, and both proteins were purified by nickel chelating chromatography. The 
purified recombinant proteins were used to develop three assays to test for 
strand transfer activity, of which two were successfully established. Furthermore, 
only INsol showed strand transfer activity in the high-throughput microtitre plate 
assay and scintillation proximity assay (SPA)-bead strand transfer assay. Activity 
of INsol was shown to be inhibited by the control compound, chicoric acid with an 
IC50 of 101.5nM in the high-throughput microtitre plate assay, whereas INsol 
activity as well as a dose response to chicoric acid with an IC50 of 248.5nM was 
recorded in the SPA-bead strand transfer assay. Visualization of radiolabelled 
enzymatic products of strand transfer by polyacrylamide gel electrophoresis of 
urea sequencing gels was unsuccessful. Overall, the high-throughput microtitre 
plate and SPA-bead strand transfer assays have been successfully established in 
our laboratories, and are available to screen compound libraries for potential 
antiretroviral drug candidates targeting integrase strand transfer. 
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1. Introduction 
1.1.  HIV: A General Background 
The Human Immunodeficiency Virus (HIV) belongs to the family Retroviridae within the 
subfamily/genus Lentivirinae. Infection with HIV ultimately leads to Acquired Immune 
Deficiency Syndrome (AIDS) in humans (Barre-Sinoussi et al. 1983; Gallo et al. 1984). By 
the end of 2008, there were 33.4 million people infected with HIV-1, with 67% living in 
sub-Saharan Africa (http:///www.unaids.org). Over 2.7 million people became HIV-1 
positive during 2008, and there were over 2 million AIDS-related deaths in the same 
year. Although there are currently over 25 approved antiretroviral drugs, there is an 
ongoing need for the discovery and development of novel, cheaper and more accessible 
antiretroviral drugs, particularly for use in the developing world.      
 
There are two types of HIV, namely HIV-1 and HIV-2. Phylogenetically, HIV-1 can be 
subdivided into 3 groups, the M (main), O (other) and N (non-M, non-O) group, where 
the M group is responsible for most HIV-1 infections globally (http://www.hiv.lanl.gov). 
Within HIV-1 group M there are 9 subtypes denoted with letters (A, B, C, D, F, G, H, J, K) 
according to their phylogenetic interpretation. Co-infection with more than one strain 
or subtype of HIV-1 could result in an inter-subtype recombination event and lead to a 
viral strain with characteristics of more than one subtype. An inter-subtype recombinant 
virus that gets transmitted and becomes one of the circulating strains in the HIV-1 
epidemic is classified as a circulating recombinant form (CRF). To date, 48 CRF’s have 
been described (http://www.hiv.lanl.gov).  
 
The HIV-1 genome consists of 9 viral genes (Figure 1.1) that encode for at least 16 
necessary proteins that aid in viral propagation. The structure of a typical HIV-1 virion is 
shown in Figure 1.2. HIV-1 has a characteristic life cycle as that of retroviruses from the 
Lentivirinae genus. HIV-1 begins its life cycle by interaction with a CD4
+
 host T cell. 
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Figure  1.1: Genetic organization of the HIV-1 genome (approximately 9.7kb). It contains 9 genes which 
code for at least 16 proteins, flanked by identical LTRs. The structural genes gag, pol and env encode for 
the Gag, Polymerase and Envelope glycoproteins, respectively. The Gag-Pol polyprotein is cleaved into the 
matrix (MA), capsid (CA), nucleocapsid (NC), P6, protease (PR), reverse transcriptase (RT) and integrase 
(IN). The regulatory genes tat and rev encode the Transcription transactivator Tat and regulatory factor 
Rev, respectively. The accessory genes vif, vpr, vpu and nef encode the viral infectivity factor, viral protein 
R, viral protein U and Negative factor, respectively. Adapted from (Sherman and Greene 2002). 
 
 
 
 
Figure  1.2: Representative structure of the HIV-1 virion and associated structural and core proteins. 
Adapted from (Sherman and Greene 2002). 
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The HIV-1 surface glycoprotein, gp120, sequentially interacts with CD4 and the co-
receptors CCR5 and/or CXCR4 on the host cell membrane. This interaction exposes the 
viral gp41 fusion protein, and allows the HIV-1 p24 core to enter the cell either by 
endocytosis or by fusion of the gp41 with the cell membrane (Goto et al. 1997). Once 
entry is accomplished, the p24 core is uncoated and HIV-1 begins to reverse transcribe 
its plus strand RNA genome into cDNA by the action of the viral Reverse Transcriptase 
(RT) enzyme. The viral cDNA is then translocated into the nucleus (in the context of a 
preintegration complex; PIC) and is integrated into the host chromosome (Haseltine 
1991). The integrated viral genome, or provirus, then undergoes transcription mediated 
with the aid of viral transcriptional factors and host transcriptional factors (Miller et al. 
2000). Viral mRNA is then translated into polypeptide chains and proteolytically cleaved 
by viral or host proteases into functional proteins. Envelope glycoproteins are 
assembled on membrane-bound ribosomes and are transported and fused to the cell 
surface as membrane bound envelope glycoproteins (Kolegraff et al. 2006). The 
essential viral proteins and viral genomic RNA are transported to the cell membrane 
where the envelope glycoproteins are present, and a new, immature virion buds out of 
the cell membrane. Once the viral protease completes full cleavage of the Gag 
polyprotein, the mature HIV-1 particle is then capable of initiating a new round of 
infection. Figure 1.3 summarizes the typical life cycle of HIV-1 [for Reviews see 
(Haseltine 1991; Goto et al. 1997; Miller et al. 2000; Kolegraff et al. 2006)].  
 
1.2. HIV-1 antiretroviral drug targets, and highly active 
antiretroviral therapy (HAART) 
Each step of the HIV-1 life cycle represents a viable antiretroviral drug target, and is the 
subject of intensive international research. To date, four classes of antiretroviral drugs 
have been approved for human use by the Food and Drug Administration of the United 
States. These classes include inhibitors which target the viral RT, protease and integrase 
enzymes, and viral entry. 
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Figure  1.3: Typical life cycle of HIV-1 showing entry, reverse transcription, integration, transcription, 
translation, assembly and budding. Adapted from (Ciuffi and Bushman 2006). 
 
Highly Active Antiretroviral Therapy (HAART) involves triple therapy consisting of a 
nucleoside analogue reverse transcriptase inhibitor (NRTI) backbone (consisting of two 
drugs) and either a non-nucleoside analogue reverse transcriptase inhibitor (NNRTI) or 
protease inhibitor. Since its introduction in 1996, HAART has significantly reduced 
morbidity worldwide, and prolonged the life-span of HIV-1 infected patients by 
preventing progression to Acquired Immunodeficiency Syndrome (Bally et al. 2004). 
However, a major downfall of HAART is that treatment failure does occur, and can be 
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attributed to patient non-adherence, poor response to antiretrovirals, toxicity to 
antiretroviral therapy or the development of HIV-1 drug resistance as a result of the 
error-prone RT enzyme during replication, or drug pressure (Perelson et al. 1996). The 
two other drug classes (integrase and entry inhibitors) are generally used as salvage 
therapy in patients that harbor multi-drug resistant virus.  
 
1.3. The HIV-1 Integrase enzyme and Integration 
During the HIV-1 replication cycle, there is a requirement that the viral genome, like 
other lentiviruses, be integrated into the host chromosome for successful propagation 
of the virus (Marchand et al. 2006). Integration occurs most efficiently after reverse 
transcription of HIV-1 RNA into cDNA (Iordanskiy et al. 2006), and is mediated by the 
viral integrase (IN) enzyme which results in a stable provirus that remains present for 
the lifetime of the infected cell. Mutations which destroy IN activity block viral 
replication (Dvorin et al. 2002), thus the integration step represents an important target 
for the development of new antiretroviral drugs.  
 
The HIV-1 IN enzyme results from the proteolytic cleavage of the gag-pol precursor and 
belongs to the transposase family of DNA transferases (Mizuuchi 1992; Rice and Baker 
2001). It has a molecular mass of 32 kDa (288 amino acids), and contains three distinct 
functional domains. The first 50 amino acids comprise the N-terminal domain (NTD) 
with zinc-binding properties (Bushman et al. 1993) which allows for increased catalytic 
activity and multimerisation of IN (Zheng et al. 1996). The Catalytic Core Domain (CCD) 
traverses residues 51–212 and contains the three highly conserved catalytically 
important residues Asp64, Asp116 and Glu152, also known as the DDE motif (Bushman 
et al. 1993). The third C-terminal domain (CTD) spanning from residues 213 to 288 is 
believed to be involved in DNA binding, oligomerization of IN in vitro (Jenkins et al. 1996) 
and interaction with RT (Dar et al. 2009). Therefore, all three domains are involved in 
oligomerization as well as specific functions within the complete IN enzyme framework 
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[for a review see (Marchand et al. 2006)]. A schematic of the IN domains is shown in 
Figure 1.4. 
 
IN catalytic activity is accomplished by the tetrameric form of the protein in vivo and can 
be divided into a two step process. The 3’-end processing (3’-P) step is the first step, 
occurring within the cytosol. A dinucleotide adjacent to a phylogenetically conserved CA 
is hydrolytically cleaved off from the 3′ end of each strand of the linear viral cDNA by IN 
(Sherman and Fyfe 1990; Bushman and Craigie 1991; Cherepanov et al. 1999). This 
results in two 3’ hydroxyl groups that are used for a subsequent nucleophilic attack 
where the two viral DNA ends are inserted by IN into the host genome in a concerted 
fashion (Charvat et al. 2006) and this step is commonly referred to as strand transfer 
(ST). ST involves attack of two phosphodiester bonds on each strand of the cellular DNA 
by the 3′-hydroxyls at the ends of the viral DNA that results in the insertion of this DNA 
product within the host genome (Bushman and Craigie 1991; Cherepanov et al. 1999; 
Charvat et al. 2006). Integration seems to be favoured at chromosomal sites where 
active genes are present (Schröder et al. 2002), while integration is disfavoured in 
condensed heterochromatin (Carteau et al. 1998) and favoured in de-condensed 
chromatin regions (Albanese et al. 2008) suggesting that integration may be influenced 
by chromatin organization or directed to these sites by a molecular chaperone. Removal 
of the two unpaired nucleotides on the 5’ viral DNA ends, also known as the DNA flap, 
and gap filling of the 5 base pair single stranded interfaces between the viral and host 
genomic DNA is then believed to be completed by the host DNA repair machinery 
[reviewed in (Marchand et al. 2006; Delelis et al. 2008)].  
 
 
Figure  1.4: Schematic of the domain structure of the HIV-1 Integrase (IN) enzyme. The functions and 
specific characterization of the domains are listed. Adapted from (McColl and Chen 2009). 
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Completion of integration results in a fully functional provirus, which can then be used 
to initiate viral DNA transcription. IN also catalyses the disintegration of half site 
integration products of viral DNA out of the host DNA (Mazumder et al. 1994; Faust et al. 
1996). IN functions while in dimeric form but is shown to exist as monomeric, dimeric, 
tetrameric, and high-order oligomeric states in vitro (Baranova et al. 2007) where 
interactions with oligonucleotides were shown to influence the IN oligomeric state 
(Baranova et al. 2007). The most accepted in vivo functional form of IN is its tetrameric 
state (Charvat et al. 2006) and more recently the crystal structure of tetrameric IN from 
prototype foamy virus, a retrovirus , in complex with viral DNA has been obtained (Hare 
et al. 2010), and may serve as a representative IN tetramer indicating the functional unit 
of IN in vivo. A schematic of the HIV-1 integration steps are shown in Figure 1.5. 
 
1.4. The Preintegration Complex and Host Factors 
Influencing Integration  
The IN enzyme functions in cells within the context of high molecular weight 
preintegration complexes (PICs) that are derived from the viral core and formed and 
mainly matured in the cytoplasm after reverse transcription of the viral RNA (Iordanskiy 
et al. 2006). The proteins forming the PIC are an assortment of both viral and host 
protein interactions. The cytoplasmic PIC creates an ideal environment for efficient 
catalysis of 3’- processing by protecting the cDNA from degradation by cellular 
nucleases. After 3’-processing, due to its karyophilic properties, IN aids the viral matrix 
(MA) and viral protein R (Vpr) in the nuclear localization of the PIC (Bukrinsky et al. 1993; 
Gulizia et al. 1994; Devroe et al. 2003), where movement into the nucleus is an energy 
dependent pathway (Bukrinsky et al. 1992). There is a possibility that IN allows for the 
movement across the nuclear membrane, (Gallay et al. 1997); however the nuclear 
import ability of IN has not been confirmed (Petit et al. 2000).  Vpr has also been shown 
to be involved in nucleocytoplasmic shuttling across the nuclear membrane (Sherman et 
al. 2001) and may play a vital role in nuclear entry of the PIC. The PIC then assists in the 
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Figure  1.5: Schematic of the HIV-1 integration reaction. The tetrameric integrase enzyme (IN) bound to 
viral cDNA generates a CA overhang in a process called 3’-end processing in the cytoplasm (i). The 
preintegration complex moves into the nucleus where the strand transfer reaction is initiated by binding 
Target DNA (ii), followed by nucleophilic attack and phosphodiester bond formation leaving a 5’ DNA flap 
(iii), DNA repair via host mechanisms, resulting in an integrated provirus (iv). Adapted from (Dar et al. 
2009).  
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DNA ST activity especially by recruitment of the cellular cofactor lens epithelium-derived 
growth factor LEDGF/p75.  
 
The precise composition of HIV-1 PICs is not known and probably changes during 
maturation from reverse transcription within the cytoplasm to integration within the 
nucleus. In addition to the viral factors HIV-1 cDNA, IN, Vpr, MA, RT and nucleocapsid 
(NC) proteins (Bukrinsky et al. 1993), known cellular host proteins which make up part 
of the PIC include the barrier-to-autointegration factor (BAF), high mobility group 
protein A1 (HMGA1), lens epithelial derived growth factor or protein p75 (LEDGF/p75), 
and others [reviewed in (Van Maele et al. 2006)]. Interestingly, components present in 
PICs, namely viral proteins, together with cellular factors are essential for the efficient 
integration of HIV-1 cDNA. In fact it has been shown that salt-stripped PICs lose their 
functionality, but can be returned to a functional state by addition of mammalian cell 
lysate and cytoplasmic extracts (Brooun et al. 2001). 
 
LEDGF/p75 has been shown to directly interact with IN in the nucleus and allow for 
chromosomal tethering and directed integration of viral cDNA at LEDGF/p75 specific 
chromosomal sites [(Ciuffi et al. 2005; Marshall et al. 2007) and reviewed in (Ciuffi and 
Bushman 2006; Engelman and Cherepanov 2008)]. In addition, LEDGF/p75 may also aid 
in stabilizing the tetramer and prevent higher oligomerization (Michel et al. 2009). The 
first host factor to be shown to interact with IN was identified as the integrase 
interactor 1 (Kalpana et al. 1994) and has been implicated in post integration activities 
by shuttling the Gag-Pol precursor polypeptide by interaction with integrase in this 
context (Yung et al. 2001). BAF appears to play a role in coordinating integration of viral 
cDNA into the host chromosome and preventing integration of the viral DNA into itself 
and HMGA1 is implicated in enhancing transcription of the HIV provirus. [for review see 
(Van Maele et al. 2006)]. Other host proteins implicated in the PIC include TNF (tumour 
necrosis factor), TRAF (TNF receptor-associated factor) and receptor-associated protein 
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(TTRAP) (Zhang et al. 2009) and TRIM (tripartite motif protein) proteins in primates 
(Anderson et al. 2006). 
 
These host cell factors may provide additional novel antiviral drug targets or impact on 
the ability of a putative IN inhibitor to successfully prevent integration. 
 
1.5. HIV-1 Integrase Inhibitors and resistance 
HIV-1 IN has no human homologue, making it an attractive target for the development 
of antiretroviral therapeutic agents with little adverse side-effects. Integration of HIV-1 
has been extensively studied since the start of the pandemic, and great advances have 
been made in the development of novel IN inhibitors (INIs), especially by the Hazuda 
group from the Merck Research Laboratories and their development of a novel IN 
activity assay (Hazuda et al. 1994) which will be discussed later in this chapter. Although 
there are relatively few clinically viable INIs to date, it must be taken into account that 
the IN-integration pathway is that of an intricate nature, spanning from the cytosol and 
ending in the nucleus with multiple proteins involved in the process. The IN protein is 
insoluble mainly due to its hydrophobic nature (Jenkins et al. 1995; Jenkins et al. 1996) 
and this characteristic of HIV-1 IN has hampered the realization of a complete crystal 
structure, which would have served well in rational design of INIs as it did for RT and 
protease (PR) enzymes. Nevertheless, due to the pioneering work of the Merck team 
and other groups, progress in the field identified compounds from the diketo acids 
(DKA) group, Naphthyridine, Equesitin, β-hydroxy keto acids group and carboxylate 
group [reviewed in (McColl and Chen 2009)]. These inhibitors either affect 3’-P and ST 
activity or ST alone. The DKA group of INIs represents the most convincing, biologically 
validated inhibitors of IN. Raltegravir (RAL, MK-0518, Isentress), a compound of the DKA 
group, was the first INI to receive FDA approval for clinical use and has also been 
allowed for use as a first-line treatment in highly active antiretroviral therapy (HAART) 
(www.fda.gov). Elvitegravir (ELV), a monoketo acid, is currently in Phase III human 
clinical trials (Sato et al. 2009), and a new experimental quad pill regime of ELV along 
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with RT inhibitors Tenofovir, Emtricitabine and a cobicistat booster has just begun Phase 
III clinical trials (http://www.hivandhepatitis.com/recent/2010/0416_2010_c.html). 
 
Structural and modelling studies have elucidated the mode of action of these 
compounds. Truncated IN has been crystallized and valuable structural data obtained 
(Cai et al. 1997; Goldgur et al. 1998; Chen et al. 2000; Wang et al. 2001; Cherepanov et 
al. 2005; Baranova et al. 2007), but the wild type enzyme is yet to be fully envisioned in 
its true form. Michel et al (2009) have obtained the outer shell of the functional 
tetrameric form of wild type IN in complex with LEDGF/p75 in the form of a cryo-
negatively stained body, and used computer-based analysis and fitting of previously 
defined crystal structures of domains to determine a possible structural orientation of 
IN. This would be the closest, thus far, in obtaining a true structure of the HIV-1 IN 
functional unit. As mentioned previously, Hare et al (2010) have determined the 
structure of the IN tetramer of prototype foamy virus (PFV), which bound HIV-1 IN 
strand transfer inhibitors, RAL and ELV (Figure 1.6). Although the IN in their study is 
from a different virus, results can be extrapolated to HIV-1 and suggest that RAL and ELV 
interact with IN’s active site only after 3’-P when the IN undergoes a conformational 
change (Baranova et al. 2007). RAL and ELV can then chelate essential metal ions (Mg
2+
 
and Mn
2+
) that bind to the IN active site. Furthermore, they are hydrophobic allowing 
them to interact with the hydrophobic pocket of the IN active site. They also interact 
with specific amino acids of the CCD, namely the DDE motif, and displace viral DNA out 
of the active site (Hare et al. 2010). The CCD domain and its associated DDE motif are 
highly conserved regions (Rhee et al. 2008) and the mechanism of action of INIs shown 
in this PFV virus may be highly related to actual method of action in wild type IN.  
 
Many resistance mutations to these INIs, especially RAL and ELV have been 
documented. Antiretroviral drug resistance mutations are caused by RT fidelity or, 
rather, the lack thereof. The main mutational pathways associated with RAL and ELV 
resistance include signature mutations at integrase positions 143, 148 and 155. The 
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three major mutation pathways, Y143, Q148 and N155 are usually accompanied by 
T97A, G140S and E92Q, respectively. To date, there are at least 30 substitutions that 
have been specifically associated with the development of resistance to RAL and/or ELV 
(http://hivdb.stanford.edu).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.6: Crystal structure of the prototype foamy virus IN active site in committed and drug-bound 
states showing IN without drug (i) and bound to RAL (ii) or ELV (iii). The top panels show protein and DNA 
cartoons, DNA bases and the side chains of indicated amino acids as sticks. The RAL and ELV drug atoms 
are colored: yellow, C; blue, N; red, O; grey, F; green, Cl. The bottom panels show the complex as a 
solvent-accessible surface, colored by atoms (light grey, C; red, O; blue, N). Grey spheres are Mn21 (i) or 
Mg21 (ii, iii) ions. Adapted from (Hare et al. 2010). 
 
1.6. HIV-1 Integrase Activity Assays 
Assays testing 3’-P generally show cleavage of the terminal 3’ CA of an oligonucleotide 
mimicking the viral LTR sequence (Sherman and Fyfe 1990). Visualization of these 
results are gel-based (denaturing polyacrylamide or agarose) making them time 
consuming and not conducive to high throughput screening.  
i ii iii 
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There are several published strand transfer assay methodologies which utilize 
recombinant integrase in either its wild type or “soluble” forms (Hazuda et al. 1994; 
Chow 1997; Bally et al. 2004) or make use of authentic PICs isolated from the cytoplasm 
of infected cells (Farnet et al. 1996; Dar et al. 2009). These approaches serve to test the 
integration of a sequence-specific viral DNA strand into a target host mimic so as to 
determine enzyme activity dynamics, allowing for the identification of possible 
inhibitors or elucidation of enzymatic activity. The PICs are prime candidates for use in 
these assays, since those that are isolated from acutely-infected cells can integrate their 
endogenous cDNA into an added Target DNA in vitro. Purified HIV-1 PICs are capable of 
incorporating 15 to 95% of the target viral DNA into an exogenously supplied DNA target 
as full-site integration products (Farnet and Haseltine 1990). However, due to the 
difficulty in isolating functional PICs, as well as developing a suitable detection method, 
it has been challenging to construct a high-throughput assay using these complexes. 
However, the Engelman group has been significantly successful in isolation of and 
development of PIC assays and their applications (Dar et al. 2009). 
 
By contrast, recombinant IN  generally tends to catalyze integration of only one DNA 
end into a given target (half-site integration), and only under specific conditions, namely 
in its tetrameric form, can it then allow for concerted ST of two viral DNA ends into a 
Target DNA in vitro (Sinha and Grandgenett 2005; Bar-Magen et al. 2009). However, 
even with these limitations, assays using recombinant IN are still the preferred method 
of testing ST, mainly due to ease, reproducibility and high throughput.  
 
The basic ideology of the ST assay utilizing recombinant IN, summarized in Figure 1.7, is 
the immobilization of a donor DNA that mimics a 3’-processed HIV-1 LTR. This takes 
advantage of the highly specific interaction of IN with the donor DNA (Hobaika et al. 
2009; Hare et al. 2010). Thereafter, IN is bound to the immobilized donor, and this 
binding is referred to as assembly. After assembly, labelled Target DNA that would 
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mimic the host integration site is added. The IN would then integrate the donor into the 
target, hence immobilizing the target. Hereafter, the labelled target is detected by a 
suitable detection method to determine integration. The Hazuda group has been the 
forerunner in development of the recombinant IN protein assays (Hazuda et al. 1994) 
and many modifications have subsequently been made to increase the efficiency and 
effectiveness of this type of assay. 
 
 
Figure  1.7: Schematic of a high throughput microtitre plate HIV-1 integration assay showing donor DNA 
immobilized on the well surface (i). After addition of IN, assembly and 3’-end processing is initiated (ii), 
followed by addition of labelled Target DNA leading to strand transfer (iii). Successful strand transfer is 
detected by relevant detection methods. Picture drawn using CorelDraw version 12.0. 
 
1.7. HIV-1 infection in South Africa 
South Africa is home to over 5.7 million people living with HIV-1, which is the largest 
infected population from a single country (http//:www.unaids.org). Most infections in 
South Africa are a result of HIV-1 subtype C transmission. There have been mild 
improvements in terms of prevalence and mortality since 2005 due to improvements in 
government policy; however, these statistics are nevertheless a daunting reality 
(http//:www.unaids.org). Access to antiretroviral drugs has escalated dramatically in 
South Africa since implementation of the government antiretroviral drug roll-out 
program in April 2004. Currently, there are over 1 million South Africans receiving 
HAART. The new first-line regimen for South African adults and adolescents effective in 
2010, consists of Tenofovir (TDF), Lamivudine (3TC)/Emtricitabine (FTC) and Efavirenz 
i ii iii 
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(EFV)/Nevirapine (NVP). In TB co-infected patients, EFV is preferred and NVP is 
administered to women of a child-bearing age who are not on reliable contraception. 
Patients on the previous d4T containing first-line regimen (d4T, 3TC, EFV/NVP) that 
exhibit no side effects remain on this regimen, and patients with contraindications for 
TDF are placed on Zidovudine (AZT), 3TC and EFV/NVP. The new second-line is 
comprised of TDF, 3TC/FTC and Alluvia (lopinavir/ritonovir) if the patient failed a d4T or 
AZT-based first-line regimen, and AZT, 3TC and Alluvia if they failed on a TDF-based first-
line regimen. (Department of Health, 2010; http://www.sanac.org.za/documents/ 
2010%20ART%20Guideline-Short.pdf). However, these regimens carry significant 
toxicities, requiring drug substitutions. In addition, an increasing number of patients 
require alternative regimens as they fail first and second-line regimens, due to non-
adherence, toxicity or development of drug resistance. Thus, the effectiveness of 
integrase inhibitors, such as RAL, needs to be investigated as alternative antiretroviral 
drug treatment options are required. In addition, a concerted effort to screen for novel 
INIs against HIV-1 subtype C needs to be undertaken.  
 
Several groups have published genotypic assays for the amplification and sequencing of 
integrase from diverse HIV-1 group M subtypes (Van Laethem et al. 2008; Eshleman et 
al. 2009; Van Baelen et al. 2009); however, none describe a subtype C specific integrase 
genotyping assay.  In addition, there is no research group in South Africa screening for 
novel INIs against HIV-1 subtype C. Thus, the overall aim of the study was to establish an 
HIV-1 subtype C specific integrase genotyping assay and strand transfer assays to screen 
for novel IN inhibitors. 
 
The specific objectives were to:   
1. Establish an HIV-1 subtype C specific integrase genotyping assay, to determine 
baseline resistance mutations to integrase inhibitors in the HIV-1 infected South 
African population. 
2. To select a representative viral isolate for isolation of preintegration complexes.  
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3. To establish strand transfer assays using HIV-1 subtype C isolated PICs, or subtype 
B purified recombinant IN that can be used to screen for novel IN inhibitors. 
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CHAPTER 2 
Materials and Methods 
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2. Materials and Methods 
2.1. Patient Samples and Reagents used In This Study 
A total of 80 HIV-1 samples from patients attending the Charlotte Maxeke Johannesburg 
Hospital (Parktown, Johannesburg, South Africa) were available for purposes of this 
study. These included 58 randomly selected patient plasma samples sent for routine 
viral load monitoring (Table 2.1; sufficient patient sample available at the time of 
sample collection) and 22 primary HIV-1 isolates from antiretroviral drug naïve AIDS 
patients isolated during 2005 (Connell et al. 2008). 
 
The following reagents were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: Sup-T1 from Dr. James Hoxie; CEM-SS 
(Cat# 776) from Dr. Peter L. Nara; CEM-GFP from Dr. Jacques Corbeil and MT-2 from Dr. 
Douglas Richman; HIV-1 NL4-3 Integrase Protein (F185H/C280S) from Dr. Robert Craigie 
as a positive control; HIV-1 IN Monoclonal Antibody (8G4) from Dr. Dag E. Helland, used 
as a primary antibody for western blot detection; Dr. Robert Craigie: pINSD.His, and is a 
expression vector that codes for integrase (IN) with a Hexahistidine motif grown in BL21 
(DE3) E. coli, and pINSD.His(Sol) which contains the HIV-1NL4-3 IN coding sequence 
from pINSD.His with modifications to introduce the amino acid substitutions Phe 
185→Lys and Cys 280→Ser. Anti-mouse IgG antibodies with horseradish peroxidase 
(HRP)-linked secondary antibodies (GE Healthcare, Waukesha, WI, US) were used for 
western blot detection. Chicoric acid (Sigma, St. Louis, MO, USA) was used as a control 
inhibitor in the modified microtitre plate assay. 
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Table  2-1: Viral loads (RNA copies/ml) and gender of the 58 randomly selected patient 
plasma samples sent for routine viral load monitoring at the Charlotte Maxeke 
Johannesburg Hospital.   
Patient 
Number 
Viral Load Gender Patient 
Number 
Viral Load Gender 
1 180 000 F 30 1.7 million F 
2 270 000 F 31 9 300 M 
3 12 000 F 32 43 000 M 
4 18 000 F 33 140 000 M 
5 6 400 F 34 3 800 F 
6 9 100 M 35 28 000 M 
7 32 000 M 36 12 000 F 
8 1 500 F 37 6 000 F 
9 11 000 F 38 43 000 F 
10 6 100 M 39 18 000 F 
11 25 000 F 40 3 800 M 
12 4 300 M 41 88 000 F 
13 3 900 M 42 5 300 F 
14 4 800 F 43 43 000 F 
15 43 000 M 44 200 000 F 
16 310 000 M 45 21 000 M 
17 21 000 M 46 930 000 F 
18 5 000 F 47 960 000 F 
19 29 000 F 48 56 000 M 
20 34 000 F 49 120 000 M 
21 19 000 F 50 4 600 F 
22 47 000 M 51 84 000 F 
23 220 000 M 52 52 000 M 
24 160 000 F 53 140 000 M 
25 260 000 F 54 540 000 M 
26 17 000 F 55 40 000 M 
27 59 000 M 56 310 000 F 
28 > 3 million F 57 78 000 M 
29 29 000 F 58 870 000 F 
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2.2. Amplification and sequence analysis of the HIV-1 
integrase  
2.2.1. Proviral DNA isolation from infected co-cultures 
Proviral DNA from the 22 viral isolates was extracted from p24 antigen-positive 
peripheral blood mononuclear cell (PBMC) cultures with a High Pure PCR Template 
Preparation Kit (Roche, Frankfurt, Germany) according to the manufacturers’ 
instructions, using all buffers supplied in the kit. Briefly, PBMC cell cultures were 
pelleted and resuspended in 200µl of phosphate buffered saline (PBS). Binding buffer 
and proteinase K were added in volumes of 200µl and 40µl, respectively. The mixture 
was then incubated at 70˚C for ten minutes. Isopropanol (Merk, Darmstadt, Germany) 
was added in a volume of 100µl, mixed and was aliquoted to the reservoir of a High 
Filter Tube fitted to a collection tube. The sample volume was then centrifuged at 8000 
x g for 1 minute (as were all subsequent spins unless otherwise stated), allowing it to 
pass through and bind the filter. Flow through was discarded and 500µl of Inhibitor 
Removal Buffer was added and centrifuged. Flow through was again discarded and 
500µl of Wash Buffer was added to the filter tube and centrifuged and flow through 
discarded. This wash step was repeated once and after discarding flow through the filter 
was centrifuged at 13000 x g for 10 seconds to remove residual wash buffer and ethanol. 
The filter was then attached to a microtube and 200µl of Elution buffer at 70˚C was 
added. The filter was centrifuged and the flow through containing proviral DNA was 
collected. 
 
2.2.2. Viral RNA isolation from patient plasma 
Viral RNA was extracted from 58 patient plasma samples using the automated Roche 
MagNa Pure LC analyzer and the MagNA Pure LC Total Nucleic Acid Isolation Kit 
(Roche), according to the manufacturer’s instructions. Fifty microliters of patient serum 
was added to 200μl of working solution from the kit, and extracted viral RNA was eluted 
in 50μl.  
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2.2.3. Reverse Transcriptase (RT) Polymerase chain reaction 
(PCR) 
The full length integrase gene was RT-PCR amplified into cDNA from the extracted viral 
RNA samples using the reverse primer SQ9RC(3) (Table 2.2). Primers used in the RT 
PCR reaction, conventional PCR and sequencing reactions were all obtained from 
Integrated DNA Technologies and are listed in Table 2.2.  
 
The Expand Reverse Transcriptase (RT) kit (Roche), was used as per the manufacturer’s 
instructions with all reagents supplied in the kit. Briefly, volumes of 10.5µl were set up 
consisting of 1µg of total extracted RNA and 25pmol of primer oligonucleotide 
(SQ9RC(3)) made up in distilled water. DNA primers and RNA template strands were 
initially denatured at 65˚C for 10 minutes using the Gene Amp PCR System 9700 
(Applied Biosystems, Foster City, CA, USA) and immediately placed on ice. The following 
reagents were then added ; reaction buffer was added to a 1X final concentration, 
dithiothreitol (DTT) to a final concentration of 10mM, dNTPs to a final concentration of 
1mM each, 20 units (U) of RNase inhibitor and 50 U of RT. The RT PCR was initiated by 
incubation at 43˚C for 60 minutes on the Gene Amp PCR System 9700 (Applied 
Biosystems) and then was stopped by placing the reaction mixture on ice. 
 
2.2.4. Conventional PCR 
The Expand High Fidelity
PLUS
 PCR system (Roche) was used for all PCR reactions. The PCR 
reaction was carried out as per manufacturer’s instructions and was shown to be 
optimal using buffer containing 1.5mM MgCl2 and 25pmol of each primer. Forward 
primer SQ7F(2) and reverse primer SQ9RC(3) were used for the PCR reaction (Table 2.2). 
Template DNA was either 5μl of isolated proviral DNA (see section 2.1 above) or RT-PCR 
product (see section 2.3 above). The total volume of the reaction was 50μl. The thermal 
cycling was carried out as per thermal profile II of the manufacturer’s instructions on the  
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Table  2-2: Primers used throughout the course of this study. 
Primer name Size (Mer) Primer sequence Experimental Use 
SQ9RC(3) 24 5’-TTGGATGTCTGCTTTCATAATGAT-3’ PCR / RT PCR 
SQ7F(2) 27 5’-AGGAGCAGAAACTTTCTATGTAGATGG-3’ PCR 
QFIN1F 20 5’-ATGGGTACCAGCACACAAAG-3’ Sequencing 
QFIN2F 20 5’-TAGCAGGAAGATGGCCAGTC-3’ Sequencing 
QFIN1R 26 5’-CTCTCCTTGAAATATACATATGGTGC-3’ Sequencing 
QFIN2R 22 5’-CTACTACTCCTTGACTTTGGGG-3’ Sequencing 
Donor 1 (D1) 32 5’-ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3’ Microplate Assay/Gel 
Assay 
Donor 2
a
 (D2) 31 5’-ACTGCTAGAGATTTTCCACACTGACTAAAAG-3’ Microplate Assay/Gel 
Assay 
Target 1
b 
20 5’-TGACCAAGGGCTAATTCACT-3’ Microplate assay /Gel 
assay 
Target 2
b
 20 5’-AGTGAATTAGCCCTTGGTCA-3’ Microplate Assay / Gel 
assay 
Donor
a
 
unprocessed 
(DU) 
21 5’-GTGTGGAAAATCTCTAGCAGT-3’ Gel Assay 
Donor
a
 
Processed (DP) 
19 5’-GTGTGGAAAATCTCTAGCA-3’ Gel Assay 
Donor Bottom 
1 (B1) 
21 5’-ACTGCTAGAGATTTTCCACAC-3’ Gel Assay (all assays)/ 
complementary strand 
Donor Bottom 
2 (B2)  
19 5’-TGCTAGAGATTTTCCACAC-3’ Gel Assay (only used in 
figure SX) 
complementary strand 
a
Donor B2 DNA was either labelled with a 5’ biotin or unlabeled at the 5’. 
b
Target DNA was either labelled with a 3’ FITC label or unlabeled at the 3’. 
 
Gene Amp PCR System 9700 (Applied Biosystems). Specifically, the cycles were set at 
94˚C for initial denaturation. Thereafter, a ten times cycle of 94˚C for 30 seconds, 57˚C 
for 30 seconds for annealing and followed by 72˚C for one minute and 30 seconds for 
elongation. Following this was a 25 times cycle of 94˚C for 30 seconds, 57˚C for 30 
seconds, followed by 72˚C for one minute and 30 seconds with an increasing increment 
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of ten seconds per cycle. This was followed by a final elongation step of 72˚C for seven 
minutes. Samples were stored at 4˚C until further use. 
 
2.2.5. PCR Fragment Purification and Visualization  
PCR fragments were purified using the high pure PCR cleanup kit (Roche) as per the 
manufacturer’s instructions, with all buffers as supplied in the kit. Briefly; the 50µl PCR 
reaction volumes from section 2.2.4 was purified by addition of 500µl of binding buffer, 
mixed and added to a High Pure Filter tube. The filter was connected to a collection tube 
and centrifuged at 13000 x g for one minute. All subsequent centrifugation steps were 
of this profile unless otherwise stated. Flow through was discarded and 500µl of wash 
buffer supplemented with ethanol was added to the filter and centrifuged. The flow 
through was discarded and 200µl of wash buffer was added and centrifuged. Flow 
through was discarded and the filter was centrifuged for 30 seconds to dry and to 
remove excess wash buffer. Elution buffer was finally added in a volume of 50µl and the 
filter was attached to a clean microtube, centrifuged and elution, containing the PCR 
DNA product, was collected and stored at -20˚C. Fragments were separated by gel 
electrophoresis using 1% agarose gels stained with 5µg/ml ethidium bromide (Biorad, 
Hercules, CA, USA) and visualized on a Chemidoc (Biorad) system.  
 
2.2.6. DNA Sequencing of HIV-1 integrase 
Sequencing was achieved using the BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems). The sequencing reaction was prepared in a total volume of 20μl 
and was carried out as per the manufacturer’s instructions. Primers QFIN1F, QFIN2F, 
QFIN1R and QFIN2R were used at 3.2pmol per reaction with 1μl of purified PCR product, 
reaction buffer and reaction mix (both supplied by the manufacturer). Thermal cycling 
was carried out on the Gene Amp PCR System 9700 (Applied Biosystems); with an initial 
single denaturation at 96˚C for 1 minute. Thereafter, in a 25 cycle format, each cycle 
begins with a ten second incubation at 96˚C; followed by a five second incubation at 
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50˚C for annealing and finally a four minute incubation at 60˚C for elongation. 
Thereafter, sequencing reactions are stored at 4˚C until further usage.  
 
The sequencing reactions were then cleaned by adding 80μl of 80% isopropanol (Merck) 
to 20μl of the sequencing reaction. The reaction was thoroughly mixed and left to 
incubate for 15 minutes in the dark. This was then centrifuged at 2000 x g for 45 
minutes on a model 5810 R Centrifuge with A-4-62 rotor (Eppendorf, Hamburg, 
Germany). The supernatant was immediately discarded by inverting the reaction plate 
and centrifuging in the inverted position at 700 x g for 1 minute. Ten microliters of HiDi 
formamide (Applied Biosystems) was then added to each sequencing reaction and the 
plates were stored at -20°C until sequencing. Sequencing was performed on the ABI 
Prism 3100- and 3730- Avant Genetic Analyzer (Applied Biosystems). Sequence data 
analysis was performed using the Sequencing Analysis V3.3 programs (Applied 
Biosystems) and assembled using Sequencher V4.5 (Genecodes, Ann Arbor, MI). 
 
For subtyping, a multiple alignment of the full length integrase region with references 
from HIV-1 subtypes A to K, CRF01_AE and CRF02_AG (http://hiv-web.lanl.gov) was 
generated in Clustal X (http://www.clustal.org). Aligned sequences were converted to 
MEGA V3.0 format, and used in phylogenetic and molecular evolutionary analyses. A 
phylogeny reconstruction of each integrase gene was performed by Neighbor-Joining 
using the Kimura two-parameter distance matrix. The stability of the nodes was 
assessed by bootstrap analysis (1000 replicates) and bootstrap values greater than 70% 
were considered significant. Nucleotide sequences were converted to amino acid 
sequences, and compared to the 2004 consensus C sequence available from the Los 
Alamos website (http://hiv-web.lanl.gov). The amino acid sequence alignment was 
extensively analyzed on GeneDoc version 2.7 (http://www.nrbsc.org/gfx/genedoc) for 
the presence of primary mutations, non-polymorphic and polymorphic mutations 
associated with resistance to known integrase inhibitors (http://hivdb.stanford.edu). 
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The integrase sequences were submitted to GenBank using Sequin V5.35 
(http://www.ncbi.nlm.nih.gov). 
 
2.3. Mammalian Cell Culture 
The SupT1, MT-2, CEM-SS and CEM-GFP suspension cell lines were maintained in 
RPMI media (Sigma) supplemented with 10% Foetal Bovine Serum (Gibco), 1% 
Penicillin and Streptomycin antibiotics (Sigma) and 1% L-Glutamine (Sigma). All cell lines 
were incubated at 37°C/ 5% CO2 unless otherwise stated. Cell lines were split as 
they became confluent at a dilution of 1:10 to 1:20. Cell stocks were made by 
resuspending confluent cells at a concentration of 10
6
 cells/ml in freezing mix 
comprised of 90% Foetal Calf Serum (Gibco) and 10% dimethylsulfoxide (DMSO) 
(Sigma). Cells were frozen in a nest box at -80°C overnight, and stored in liquid 
nitrogen. 
 
2.4. HIV-1 Preintegration Complex Isolation 
2.4.1. HIV-1 subtype C Infections  
HIV-1 infections were done using a cell-line adapted isolate 05ZAFV3 available in 
our laboratory (previously propagated in a U87 cell line). SupT1, MT-2, CEM-SS and 
CEM-GFP cells were cultured as explained above until confluent and counted with a 
haemocytometer. For infections; 3x10
6
 cells were seeded in 5ml culture media and 
150µl of HIV-1 FV3 containing supernatant was added, and culture was incubated 
overnight. There after the culture media was changed by pelleting the cells followed 
by resuspension in 5ml of fresh media. Cell culture was then incubated at 37˚C/5% 
CO2 until usage in co-infections. 
 
The Murex HIV Antigen mAb (Abbott, Illinois, USA) p24 ELISA detection assay was 
used to determine viral infection, as per the manufacturer’s instructions. Briefly, 
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culture supernatant samples were diluted into 100μl volumes and added to the 
anti-p24 wells. Conjugate solution 1 was added in a 100μl volume and incubated at 
37˚C for one hour. The wells were washed on an ELX50 Auto Strip Washer (BioTek 
Instruments Winooski, VT, United States) with available wash buffer and 200μl of 
conjugate 2 was added to the wells. This was incubated at 37˚C for 30 minutes. The 
wells were once again washed and 200μl of the substrate was added and incubated 
at room temperature for 30 minutes. A 50μl volume of HCl (1M) was added to stop 
the reaction. Binding was then calculated on an ELX808 Elisa plate reader (BioTek 
Instruments) using a dual wavelength (450nm and 690nm) protocol. 
 
2.4.2. Crude Extraction of HIV-1 PICs 
The following method was adapted from Brooun et al. (2001), Briefly, once infection 
was established, as determined by p24 ELISA, usually on day ten, the infected cells 
were co-cultured with a ten-fold concentration of uninfected SupT1 cells, and 
incubated for a further seven hours. Cells were then pelleted at 160 x g for five 
minutes and the supernatant was discarded. Cells were washed with buffer A 
(10mM Tris-HCl (Sigma) pH7.4; 15mM KCl (Sigma); 5mM MgCl2 (Sigma) and 20μg/ml 
aprotinin (Sigma)) and pelleted at 160 x g for five minutes. Supernatant was 
discarded and cells were resuspended in lysis buffer (buffer A with 0.025% digitonin 
(Sigma)) at a concentration of 2.0 x 10
7
 cells/ml based on original cell counts. The 
solution was left to incubate at room temperature for ten minutes, thereafter, 
nuclei were pelleted at 1000 x g for three minutes. Aliquots of supernatant were 
carefully removed and sucrose (Sigma) was added to a final concentration of 8% for 
each aliquot. This was then snap frozen in liquid CO2 and stored at - 80˚C. 
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2.5. HIV-1 Recombinant Integrase Purification 
2.5.1. Preparation of competent Escherichia (E.) coli 
E. coli BL21 pLysE cells (Novagen, Darmstadt, Germany) were made competent by 
standard protocols. Briefly, overnight cultures of BL21 pLysE cells were propagated 
to make competent cells. These were diluted 25 times in Luria Broth supplemented 
with 50µg/ml chloramphenicol (Calbiochem, Darmstadt, Germany) and incubated at 
37°C, in a shaking incubator, until the OD reading at 600nm reached 0.4. Cells were 
incubated on ice for ten minutes and then centrifuged at 2000 rpm/4°C (Eppendorf) 
for 15 minutes. The supernatant was removed and discarded and the pellet was 
resuspended in 16 ml autoclaved transformation buffer (100mM CaCl2 (Sigma); 
10mM Pipes-HCl (Merk) pH 7; 15% glycerol (Melford Labs, Ipswich, US). This was 
incubated on ice for 30 minutes and then centrifuged at 1500 rpm/4°C for 15 
minutes. Supernatant was once again discarded and the pellet was gently 
resuspended in 4ml transformation buffer (and kept on ice). Aliquots of 200µl were 
stored at -80°C. 
 
2.5.2. Bacterial Transformations 
Competent BL21 (DE3) pLyse cells were transformed with the pINSD.His 
recombinant plasmid (see section 2.1). Briefly, 1µl of pINSD.His was added to 100µl 
of thawed competent BL21 pLyse cells and incubated on ice for 30 minutes. The 
solution was then heat-shocked at 37°C for 90 sec and placed on ice for five 
minutes. The solution was then plated on agar plates supplemented with 100µg/ml 
ampicillin (Melford Labs) and 50µg/ml chloramphenicol and incubated at 37°C 
overnight. Colonies that showed ampicillin resistance were selected as transformed 
bacteria (BL21 pINSD.His) and used in subsequent analyses. 
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2.5.3. Gene Induction 
BL21 pINSD.His and pINSD.His(sol) cells were induced for gene expression. Firstly, 
Luria Broth supplemented with ampicillin (100µg/ml) and chloramphenicol 
(50µg/ml) was inoculated with BL21 pINSD.His and incubated overnight at 37°C 
shaking. This was then diluted 50 times and incubated at 37°C and allowed to reach 
an OD between 0.5 – 0.8 at 600nm. Isopropyl β-D-1-thiogalactopyranoside 
(Calbiochem) was then added to the culture at a 1mM concentration. The culture 
was then incubated at 37°C shaking for an optimal time period of three hours. 
Induced BL21 pINSD.His bacteria were then harvested by centrifugation at 4000 rpm 
(Eppendorf) for 30 minutes and resuspended in binding buffer (1M NaCl (Sigma); 
20mM Tris (Sigma) pH 7.9; 5mM imidazole (Sigma)) and stored at -20°C. 
 
2.5.4. Bacterial Cell lysis and Fraction isolation 
Induced BL21 pINSD.His cells were lysed by sonication. Sonicator (Bandelin) settings 
were 30 seconds for six cycles at 75-80 Hz, and this was repeated five times. The 
sonicate was then centrifuged at 40 000 x g on an Optima L-80 XP Ultra Centrifuge 
(Beckman, Brea, CA, USA) set at 4˚C. Supernatants were collected as the soluble 
fraction and depending on usage was stored on ice or at -20˚C.  
 
Induced BL21 pINSD.His(sol) cells were resuspended in lysis buffer (1M NaCl, 20mM 
HEPES, 5mM imidazole, 0.25% CHAPS (Sigma), 1mM PMSF (Sigma), 35 U of DNAase1 
(Sigma)) and incubated on ice for 30 minutes. Cells were then lysed by 
homogenizing five times for 1 minute using a homogenizer (Bandelin), followed by 
sonication, three times in a sonicator bath (Bandelin) for 1 minute. Finally, the 
lysate was centrifuged at 15 000 x g for 30 minutes on a model 5810 R Centrifuge 
with A-4-62 rotor (Eppendorf) and enzyme containing supernatant was collected 
and immediately used in subsequent purification. 
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2.5.5. Nickel Chelating Column Chromatography  
The following method for protein purification was used for wild type IN (INwt) 
proteins only which were induced from pINSD.His. Nickel-bound resin was prepared 
by incubation of 0.1M NiSO4 (Sigma) to sepharose beads on ice for 15 minutes and 
then equilibrated with binding buffer for five minutes on ice. Resin and protein 
fractions were then mixed and incubated in a 50ml tube (Nunc), shaking at 4˚C 
overnight. The mixture was then added to a Luer-Lock, Non-jacketed Liquid 
Chromatography Column (Sigma) and resin was allowed to pack by gravity while a 
flow through sample was collected. Two hundred millilitres of two wash buffers 
each (1M NaCl (Sigma); 50mM Sodium Phosphate Buffer (Sigma) pH 8; 50mM 
imidazole (Sigma)) and (1M NaCl (Sigma); 50mM Sodium Phosphate Buffer (Sigma) 
pH 8; 100mM imidazole (Sigma)) were sequentially allowed to flow through the 
column using the Biologic LP System (Biorad) at a flow rate of 3.5ml/minute. The 
protein was then eluted with 25ml elution buffer (1M NaCl (Sigma); 50mM Sodium 
Phosphate Buffer (Sigma) pH 8; 500mM imidazole (Sigma)) at a flow rate of 
1ml/minute. Eluate was dialyzed against buffer (1M NaCl (Sigma); 20mM HEPES 
(Sigma) pH 7.5; 0.1mM ethylenediaminetetraacetic acid (EDTA) (Sigma); 1mM DTT 
(Sigma); 10% glycerol (Melford Labs)) overnight at 4˚C. Dialysed eluate was then 
concentrated using 10kDa centricon tubes (Millipore, Billerica, MA, USA).  
 
The following protocol was used for purification of the soluble mutant of IN (INsol) 
from induced bacteria transformed with pINSD.His(sol). A pre-packaged 5ml HisTrap 
HP Column (GE Healthcare) was attached to the ACTAPrime Plus (GE Healthcare) 
and equilibrated with binding buffer (1M NaCl (Sigma), 20mM HEPES (Sigma) pH 7, 
5mM imidazole (Melford Labs)) and loaded with 10ml of sonicated supernatant 
containing His-tagged protein. After protein binding, the column was washed with 
100ml of binding buffer at a flow rate 2ml/minute allowing for the pressure to be 
below the maximum of 0.3 mp. All flow rates were the same for subsequent washes 
unless otherwise stated. Thereafter, the column was washed with 200ml of wash 
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buffer 1 (1M NaCl (Sigma), 20mM HEPES (Sigma) pH 7, 60mM imidazole (Melford 
Labs)) followed by 200ml of wash buffer 2 (1M NaCl (Sigma), 20mM HEPES (Sigma) 
pH 7, 150mM imidazole). Nickel-bound proteins were eluted using a linear gradient 
of imidazole ranging from 150mM to 600mM at a flow rate of 1ml/minute. The 
gradient was set to 150 ml final volume. Elution was measured 
spectrophotometrically and was monitored with PrimeView (GE Healthcare). 
Fractions with protein were collected (fractions 23-60) and were pooled and 
concentrated using 3kDa centricon tubes (Millipore). Buffer exchange was achieved 
by passage through a p10 G25 Sephadex column (GE Healthcare). 
 
2.5.6. Sodium Dodecyl Sulphate–Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Western Blotting 
The isolation of PICs and recombinant INwt and INsol protein expression was investigated 
by SDS-PAGE and Western blot analysis. SDS-PAGE gels of 12.5% were prepared and 
nitrocellulose (Amersham, Waukesha, WI, US) was blotted according to Hoefer 
guidelines. Briefly, the isolated PICs and recombinant protein samples were added to 
equal amounts of loading buffer (0.5M Tris-HCl pH 6.8, 5% glycerol, 2% SDS and 100mM 
DTT) and electrophoresed on 12.5% polyacrylamide gels at a current of 10 milliamperes 
(mA) initially until the prestained molecular weight marker (New England Biolabs, 
Ipswich, MA, US; Fermentas, Maryland, USA) entered the running gel, then current was 
increased to 30mA per gel. The gels were then equilibrated with transfer buffer and 
proteins were transferred to the nitrocellulose membrane (Amersham) for 50 minutes 
at 50mA using the TransBlot SD Semi-Dry Electrophoretic Transfer Cell (BioRad). 
Nitrocellulose membranes were blocked with 5% skim milk powder in 1 x Tris Buffered 
Saline (TBS) (50mM Tris (Sigma) pH 7.6, 150mM NaCl (Sigma)) for one hour. The 
membrane was then washed with 0.1% Tween-TBS three times for five minutes. Primary 
antibodies used were HIV-1 IN Monoclonal Antibody (8G4) and membranes were 
incubated at a concentration of 1:500 for one hour. The membrane was washed as 
before and anti-mouse horse radish peroxidase (HRP)-linked secondary antibody (GE 
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Healthcare) was incubated with the membrane in a 1:3000 concentration for one hour. 
The membrane was washed as before. Super Signal West Pico Chemiluminescent 
Substrate (Pierce, Rockfork, IL, USA) was prepared by addition of equal amounts of 
Super Signal West Pico Sable Peroxide to Super Signal West Pico Luminol/Enhancer 
Solution. The substrate was incubated with the membrane at room temperature and 
fluorescence was visualized on a Chemidoc system (Biorad). 
 
2.6. Functional analysis of purified recombinant IN  
Purified recombinant IN protein was used to set up and optimize three different assays 
to test for one-site integration activity using a high throughput microtitre plate and SPA 
HIV-1 integration assay, and full-site integration using a gel-based HIV-1 integration 
assay.   
 
2.6.1. High throughput microtitre plate HIV-1 integration assay 
Microplate analysis for recombinant INwt and INsol protein functionality was performed 
using the fluorescent properties of a FITC (fluorescein isothiocyanate) labelled primer 
bound to a biotinylated donor immobilized in streptavidin coated wells. Oligomeric 
primers used for this experiment are listed in Table 2.2. The oligomers and their 
complementary strands were annealed by heating to 95˚C for five minutes and 
allowed to slowly reach room temperature. This yielded donor: Donor 1/Donor 
2(5’Biotin) and target: (3’ FITC) Target 1/Target 2(3’ FITC) pairs. Immobilizer 
streptavidin F96 Black (Nunc) plates were firstly primed as per manufacturer’s 
instructions with the biotinylated donor. Briefly, wells used for the test were 
washed three times with 5 x SSCT buffer (750mM NaCl (Sigma), 75mM Sodium 
Citrate (Sigma), 0.05% Tween 20 (Sigma)). Biotinylated donor DNA was prepared in 
5 x SSCT at a concentration of 50mM, and 100μl was added to each test well. The 
plates were incubated at room temperature for one hour with gentle agitation. 
Thereafter, wells were aspirated and washed with 2 x SSCT (150mM NaCl (Sigma), 
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15mM Sodium Citrate (Sigma), 0.05% Tween 20 (Sigma)) three times. Purified IN 
was diluted to a concentration of 1μM in Assay Buffer 1 (20mM HEPES (Sigma) pH 
7.3, 75mM NaCl (Sigma), 10mM MnCl2 (Sigma), 2μM ZnCl2 (Sigma), 1% glycerol 
(Melford Labs)) or Assay Buffer 2 (25mM HEPES (Sigma) pH 7.5, 10mM MgCl2 
(Sigma), 5mM DTT (Sigma), 10% polyethylene glycol (PEG) 8000 (Sigma), 10% DMSO 
(Sigma), 20μM ZnCl2 (Sigma), 75mM NaCl (Sigma)) and 100μl was added to each test 
well, while negative control wells contained only Assay Buffer. Plates were then 
incubated for 30 minutes at 37˚C with gentle agitation. Wells were then washed 
with Assay Buffer 1 or Assay Buffer 2 two times with 5 minute incubations per wash. 
FITC labelled Target DNA was then diluted in assay buffer to various concentrations 
to determine the optimal concentration, and 100μl was added to each test well 
including the negative control wells. The plates are incubated at 37˚C for one hour 
with gentle agitation. Wells were then washed three times with 300μl of 2 x SSC 
(150mM NaCl (Sigma), 15mM Sodium Citrate (Sigma)) with ten minute incubations 
per wash. Finally, wells were read on an Appliskan fluorometer (Thermo Electron 
Corp. Rockfork, IL, USA) with excitation wavelength of 485nm and emission 
wavelength of 535nm and data was recorded with SkanIt RE 2.3 software (Thermo 
Electron). 
 
A modification to the abovementioned protocol was carried out to improve the 
recombinant INsol protein detection. The oligonucleotides used were the same as 
above. Donor substrate at a concentration of 140nM was diluted in a donor dilution 
buffer (25mM Tris-HCl (Sigma) pH 7.5, 150mM NaCl (Sigma), 0.05% Tween-20 
(Sigma), 100µg/ml BSA (Sigma)) and added to Even Coat Streptavidin-coated 
microplates (R & D Systems, Minneapolis, MN, US). These were incubated at room 
temperature for 1 hour with gentle agitation. Unbound donor substrate was then 
removed by three washes with 300µl PBS. IN enzyme was then prepared in Assay 
Buffer 1 to a concentration of 1µM and 100µl added to each well and incubated at 
room temperature for 30 minutes with gentle agitation. The plates were washed 
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twice with Assay Buffer 1 with gentle agitation at room temperature for five 
minutes. Assay Buffer 1 was then added to each well in a volume of 90µl or 80µl 
and 10µl of 100% DMSO or Chicoric inhibitor (Sigma) and the plates were incubated 
at 37˚C for 30 minutes. Target substrate was diluted in Assay Buffer 1 to a 
concentration of 2.5µM and 10µl were added per well (final concentration of 
250nM). Plates were incubated at 37˚C for one hour and thereafter washed three 
times with 2 x SSC with 10 minute incubations per wash at room temperature with 
gentle agitation. Monoclonal Alkaline Phosphatase conjugated anti-FITC antibody 
(Sigma) was prepared by 10 000 times dilution in Tween (0.05%)-TBS (T-TBS) and 
200µl was added to the wells and incubated at room temperature for two hours 
with gentle agitation. Plates were then washed three times with TBS for ten 
minutes per wash at room temperature with gentle agitation. para-
Nitrophenylphosphate (pNPP) substrate (Sigma) was added to each well in a volume 
of 200µl and incubated at 37˚C for one hour with gentle agitation. The reactions 
were then stopped by dilution of the 3µM NaOH stock to a final concentration of 
50nM. Absorbance of the wells was measured at 405nm using the xMark Microplate 
Absorbance Spectrophotometer (Biorad). 
 
2.6.2. HIV-1 Integrase Urea-PAGE Based Functional Analysis 
Gel-based IN functional analysis was undertaken utilizing the DNA separation properties 
of Urea-PAGE. Assay conditions were as follows; firstly, IN proteins were diluted in 50μl 
Assay Buffer 1 (20mM HEPES pH 7.3, 75mM NaCl, 10mM MnCl2, 2μM ZnCl2, 1% 
glycerol) or Assay Buffer 2 (25mM HEPES pH 7.5, 10mM MgCl2, 5mM DTT, 10% PEG 
8000, 10% DMSO, 20μM ZnCl2, 75mM NaCl) to varying concentrations. Unlabelled or 
radiolabelled Donor DNA (Table 2.2, Donor 1, DU and DP) was diluted with 25μl of 
varying assay buffers to varying concentrations and added to the diluted IN proteins. 
The reaction was incubated for 30 minutes on ice to allow for IN/DNA complex 
formation. Radiolabelled Target DNA (Table 2.2, Target 1 and Target 2) was diluted in 
25μl of varying assay buffers to varying concentrations and added to the reaction 
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mixture. The reaction mixture was incubated for 30 minutes on ice and thereafter for 
one hour at 37°C to allow for ST. The reactions were stopped by adding 20μl formamide 
loading buffer (95% formamide (Sigma), 0.025% bromophenol blue (Sigma), 0.5μM 
EDTA (Sigma)). Thereafter, reactions were denatured at 95°C for 5 minutes and placed 
on ice or stored at -20°C. Urea-PAGE Gels were prepared as 20% acrylamide gels (20% 
polyacrylamide (Merk), 8M Urea (Sigma), 89mM Tris (Sigma), 89mM Boric acid (Sigma), 
2mM EDTA (Sigma)). Gels were pre-run at 200 volts for one hour in TBE (89mM Tris 
(Sigma), 89mM Boric acid (Sigma), 2mM EDTA (Sigma)) tank buffer heated to 70°C. 
Reaction samples were added to the wells and were electrophoresed at 150 volts for 
two hours (until the dye front exited the gel completely). Gels were then wrapped in 
cellophane paper and exposed to Kodak CL-Xposure X-ray film (Sigma) for 24 hours at     
-70°C. The X-ray film was then developed in the dark by five minute incubation in Kodak 
developer (Sigma), followed by a one minute wash in distilled water. Finally, the 
developed film was fixed in Kodak Fixer (Sigma) for three minutes and washed with 
distilled water for 1 minute and allowed to air dry. 
 
2.6.3. HIV-1 Integrase Scintillation proximity assay Strand 
Transfer Assay  
2.6.3.1. Preparation of SPA Bead complex 
Further functional analysis was undertaken utilizing the scintillation properties of 
streptavidin-coated scintillation proximity assay (SPA) beads (GE Healthcare). SPA beads 
were prepared by resuspension in SPA buffer containing NaCl (27.8mM HEPES (Sigma) 
pH 7.8, 27.8mM MgCl2 (Sigma), 111.1μg/ml BSA (Sigma), 5.56mM β-mercaptoethanol 
(Sigma), 50mM NaCl (Sigma)) to a concentration of 10mg/ml. Biotinylated donor DNA 
from Table 2.2 was added to the suspension at a final concentration of 360nM. The 
mixture was then rocked at room temperature for 30 minutes. Thereafter, the SPA 
beads are centrifuged at 870 x g for five minutes and the supernatant discarded. The 
pellet was resuspended in 500μl of SPA buffer (NaCl+) and centrifuged at 870 x g for five 
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minutes. The supernatant was discarded and the pellet was resuspended in 2.5ml of SPA 
buffer containing no NaCl. IN proteins were diluted in Integrase Control Buffer (50mM 
Tris-HCl (Sigma) pH 7.8, 1M NaCl (Sigma), 2mM β-mercaptoethanol (Sigma), 20% 
glycerol (Melford Labs)) to 4μM and added to the prepared SPA bead suspension to a 
final concentration of 0.5μM. This solution was then rocked at room temperature for 30 
minutes and the resultant IN/Donor/SPA bead complex was stored at 4˚C for not more 
than two weeks.  
 
2.6.3.2. Radiolabelling of DNA 
Donor and Target DNA (Table 2.2) were radiolabelled using the DNA 5’ End-Labeling 
System (Promega, Madison, WI, USA) as per the manufacturer’s instructions. Briefly, 
10pmol of the oligomer substrate (D1, DP, DU and either target) was added to a 50 μl 
reaction of 1 x calf intestinal alkaline phosphatase reaction buffer and 0.1 units of calf 
intestinal alkaline phosphatase. Reaction mixtures were incubated first at 37°C for 15 
minutes and then at 56°C for 15 minutes. Thereafter, an additional 0.1 unit of calf 
intestinal alkaline phosphatase was added and the above incubations were repeated. 
Tris-EDTA-saturated phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) was added to 
the reactions, vortexed and centrifuged at 12 000 x g for two minutes, and the upper 
aqueous phase was aspirated and placed in a clean microtube. The phenol extraction 
was repeated and the upper aqueous phase was extracted to a fresh microtube and 
NaCl was added to a final concentration of 0.5M. Two volumes of ethanol were then 
added and the solution was vortexed and centrifuged at 12 000 x g for 15 minutes. The 
ethanol was aspirated and the pellet was allowed to air dry until no liquid ethanol was 
present. The pellets containing the dephosphorylated oligomers were then resuspended 
in 29μl of distilled water. All oligomer substrates were then phosphorylated with 
32
P, 
and Target DNA for the SPA bead Stand Transfer assay was also labeled with 
33
P in a 
50μl reaction containing the 29μl dephosphorylated target substrate (10pmol), 1X T4 
polynucleotide kinase reaction buffer, 100μCi of 
32
P or 50μCi 
33
P 3000Ci/mmol Easy 
Tides Adenosine 5’-triphosphate (Perkin Elmer Inc., Boston, MA, US) and 10 units of T4 
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polynucleotide kinase. The reactions were incubated at 37°C for 10 minutes, and then 
stopped with 2μl of 0.5M EDTA. The solutions were then heat inactivated for 1 minute 
at 78°C. Thereafter 10pmol of complementary strands were added. The solutions were 
heated to 95°C for five minutes and allowed to cool to room temperature to allow for 
annealing. 
 
2.6.3.3. SPA bead Strand Transfer Assay set up 
Reactions were prepared in a 96 well plate in 100μl reactions by diluting 50μl of SPA 
bead complexes (section 2.6.3.1) in 40μl of Bead assay buffer (25mM HEPES (Sigma) pH 
7.8, 62.5mM NaCl (Sigma), 31.25mM MgCl2 (Sigma), 100μg/ml BSA, 5mM β-
mercaptoethanol (Sigma)) or 30μl of Bead assay buffer and 10μl of chicoric acid with 
pre-incubation with inhibitor for 1 hour. Radiolabelled 
33
P-Target DNA was diluted to 
1μM with Target Dilution buffer (25mM HEPES (Sigma) pH 7.8, 100μg/ml BSA (Sigma), 
5mM β-mercaptoethanol (Sigma)) and 10μl was added to reactions at a final 
concentration of 100nM and incubated at 37°C for one hour. Reactions were stopped 
with 50μl of 3 x Quenching solution (6M CsCl (Sigma), 0.5M EDTA (Sigma)). The 
scintillation was measured using a TopCount Microplate Scintillation Counter (Perkin-
Elmer Inc.) 
 
2.6.4. Data analysis 
All data and graphs for the functional assays were analyzed in GraphPad Prism version 
5.1. Unpaired Students t-tests were used to compare individual columns while a Non-
Linear curve fitting for (Log)inhibitor vs response was used to calculate IC50 values. 
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CHAPTER 3 
Results 
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3. Results 
3.1. Amplification and sequencing of HIV-1subtype C 
integrase 
An RT-PCR and PCR protocol for the amplification of an approximately 1.3kb fragment 
encompassing the HIV-1 integrase was successfully established. RT-PCR and PCR 
amplification was successful for 73 of the 80 (91.3%) study samples, and included all of 
the 22 proviral DNA samples (Figure 3.1), and 51 of the 58 patient plasma samples 
(Figure 3.2).  
 
Patient viral loads for the samples that were successfully amplified ranged from greater 
than 3 million to 1500 RNA copies/ml (Table 2.1). Of the 51 samples that were amplified, 
41.4% were from male patients. 
 
All 73 amplicons were successfully sequenced and analyzed. Nucleotide sequences of 
the 73 newly characterized full-length integrase genes ranged from 867 to 876 base 
pairs, with intact open reading frames confirming the presence of functional integrase 
genes in all patients and primary virus isolates. The integrase intrasubtype nucleotide 
diversity for all 73 newly characterized samples varied between 2.2% and 7.9 %.  
 
Phylogenetic analysis of the full-length integrase nucleotide sequences, together with 
viruses from the major subtypes revealed that 71 sequences clustered within HIV-1 
subtype C with a bootstrap value of 100%, while two samples (09ZAP35 and 09ZAP52) 
showed evidence of recombination (Figure 3.3). These two sequences were further 
analyzed using the RIP 3.0 Program (http://hiv-web.lanl.gov) (Figure 3.4), which showed 
that sample 09ZAP52 was a unique GC recombinant with a region at the 3’-end of the 
gene that was unassigned, since it showed similarity to an AE recombinant, a CY 
recombinant or an A subtype. 09ZAP35 was shown to be a unique AC recombinant.  
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All sequences were submitted to Genbank using the Sequin (version 9.5) program 
available from the national centre for biotechnology information website 
(http://www.ncbi.nlm.nih.gov) and are available under the accession numbers 
GQ872465 to GQ872538. 
 
The nucleotide sequences were converted to amino acid sequences and an alignment of 
all 73 integrase sequences was compared and extensively analyzed. A distribution of the 
variants is shown in Figure 3.5. The proteins varied from 288 to 292 amino acids in 
length, primarily due to insertion of an unusual tetra-peptide insertion (QNME) in the C-
terminus of the protein in 23 samples.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.1: A representative 1% agarose gel showing integrase PCR products amplified from extracted 
proviral DNA. The names of the proviral isolates are indicated above the wells. A 1kb DNA size marker 
(New England Biolabs) is indicated on the left. The arrow indicates the approximately 1.3kb PCR amplicon.  
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Figure  3.2: A representative 1% agarose gel showing integrase RT-PCR products amplified from extracted 
viral RNA. The patient numbers are indicated above the wells. A 1kb DNA size marker (New England 
Biolabs) is indicated on the left. The arrow indicates the approximately 1.3kb PCR amplicon. 
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Figure  3.3: Phylogenetic relationships of the 73 newly characterized full-length integrase sequences with 
HIV-1 subtype reference sequences from the Los Alamos database (http://hiv-web.lanl.gov). The unique 
recombinant sequences are shown in red. Phylogenetic trees were constructed from nucleotide sequence 
alignments, using neighbor joining and the Kimura two-parameter distance matrix. The reliability of the 
branching order was estimated from 1000 bootstrap replicates, and only bootstrap values of 70% or 
higher are shown.  
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Figure  3.4: RIP 3.0 analysis of 09ZAP52 (top) and 09ZAP35 (bottom). The program compares the query 
sequence to a database of HIV-1 subtypes and selected recombinants and plots the similarity (s(K)) of the 
query sequence to background sequences (see key for different subtypes tested) at each nucleotide 
position (k). 09ZAP52 is shown to be a GC recombinant with part of its sequence not generally clear but 
possibly holding similarities to an AE recombinant around nucleotides 570 to 670. 09ZAP35 is shown to be 
an AC recombinant but also has high similarities to an AE recombinant between nucleotides 600 and 730. 
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Figure  3.5: Distribution of variants amongst the 73 newly characterized full-length integrase sequences. 
The consensus subtype C sequence is shown at the top of each 30 amino acid sequence section, below 
which is the number of annotated sequences containing an unambiguous amino acid at the indicated 
position. Beneath are the variants with the superscript numbers indicating the amount of times that they 
occurred. Domains and important residues are highlighted. The N-terminal domain is highlighted in yellow, 
the catalytic core domain in white and the C-terminal domain in blue. The catalytic triad residues are 
indicated in red and relevant integrase inhibitor resistance mutations are in green. 
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3.2. HIV-1 subtype C cell line infections, and detection of 
Preintegration Complexes 
Attempts were made to infect all four cell lines (SupT1, CEM-SS, CEM-GFP and MT-2) 
with the HIV-1 subtype C FV3 viral isolate (CXCR4 utilizing). Despite repeated attempts, 
the CEM-SS and CEM-GFP cell lines were impervious to infection with FV3 (data not 
shown). By contrast, SupT1 and MT-2 cell lines were easily infected by FV3. Initial 
infection of SupT1 cells took approximately 21 days before the infection was detected 
by p24 antigen ELISA. FV3 virus adapted for growth on SupT1 cells was able to infect 
MT-2 cells within 5 days. Thereafter, viral infection of both MT-2 and SupT1 cells was 
allowed to continue up to day 13, as determined by p24 antigen ELISA (Figure 3.6) 
before use in all the SupT1 co-culture experiments.  
 
PICs were isolated from SupT1/SuptT1 and MT-2/SuptT1 co-cultures, as described in 
sections 2.4.1 and 2.4.2 and analyzed by SDS-PAGE and Western blot analysis. 
However, despite repeated attempts, Western blot analysis of PIC isolation extracts, 
using the HIV-1 IN Monoclonal Antibody (8G4) antibody were negative for IN (results 
not shown). Further optimization of co-culturing conditions and different PIC 
isolation protocols were unsuccessful. Thus, purification of recombinant IN was 
undertaken.   
 
3.3. HIV-1 subtype B recombinant Integrase Protein 
Isolation 
Expression of the HIV-1 subtype B recombinant protein in transformed bacteria (E. coli 
BL21 pINSD.His) was detected as early as one hour post-induction with 1M IPTG, as 
determined by SDS-PAGE and Western blot analysis (Figure 3.7). Expression levels were 
sufficient after three hours post-induction with 1mM IPTG, and used to harvest bacterial 
cells in all subsequent experiments.  
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Figure  3.6: OD readings of the p24 antigen ELISA results showing infection of MT-2 cells and SupT1 with 
the FV3 viral isolate. OD readings of samples on day 0 and day 13 were taken. The key indicates cell lines 
infected. Levels of p24 were above the upper limit of OD reading of 3 on day 13. 
 
The control HIV-1 HXB2 (subtype B) recombinant protein (INwt) was approximately 
32kDa, as expected, whereas the expressed recombinant subtype B proteins was 
approximately 34.5kDa, due to the presence of extra amino acids from the His-tag and 
thrombin cleavage site. 
 
The INwt was then tested for solubility by observing the bacterial cell fraction in which 
the protein appeared to be concentrated. SDS-PAGE and Western blot analysis of E. coli 
BL21 pINSD.His supernatant and pellet samples indicated that the protein was not 
secreted into the culture media (Figure 3.8.). Furthermore, the supernatant and pellet 
samples obtained after sonication of the cell lysate showed very low protein 
concentrations in the sonicated supernatant fraction, while most of the IN protein was 
concentrated in the sonicated pellet fraction (Figure 3.8). The presence of the protein, 
predominantly in the sonicated pellet fraction, indicates that the protein is insoluble. No 
attempts were made to purify IN from the insoluble fraction, and the soluble fraction 
became the focus of subsequent purification procedures for INwt.  
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The soluble fraction of the INwt was successfully purified by Nickel Chelating Column 
Chromatography, as determined by SDS-PAGE and Western Blot analysis (Figure 3.9). 
The protein purification yielded virtually uncontaminated soluble IN protein in the 
eluate. However, a significant amount of the expressed INwt was lost in the flow 
through or remained attached to the resin after elution (Figure 3.9).  
 
In an attempt to optimize the purification protocol, the recombinant IN was eluted 
with different concentrations of imidazole. Figures 3.9 and 3.10 compare elution of 
IN at concentrations of 350mM and 500mM, respectively. When eluted with a 
higher concentration of imidazole there was no improvement of INwt detaching 
from the resin; however, an increased number of contaminating proteins was noted 
(Figure 3.10.). In addition, when the 350 and 500mM eluates were concentrated 
through the 10kDa size exclusion column they formed large aggregates. Because the 
purified recombinant protein yields were adequate for the purposes of this study, 
we did not attempt to further optimize the purification protocol. 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.7: SDS-PAGE (left) and corresponding Western Blot (right) of induced BL21 pINSD.His cultures. 
Samples were taken at 1 hour intervals up to 3 hours after 1mM IPTG was added to the bacterial culture. 
Protein molecular weight markers (in kDa; kilodalton) are indicated on the left. The arrow indicates the 
expressed IN protein. 
30kDa 
INsol 
7kDa 
175kDa 
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Figure  3.8: Western Blot analysis of induced E. coli BL21 pINSD.His bacterial samples. Lanes demarcated 
as Supernatant and Pellet were samples from E. coli BL21 pINSD.His that were not sonicated prior to 
centrifugation. Lanes demarcated as Lysate Supernatant and Lysate Pellet were samples taken after 
sonication and centrifugation. The Pellet sample indicates total protein (soluble and insoluble). The arrow 
indicates the expressed IN protein (approximately 34.5kDa). 
 
 
   
 
 
 
 
 
 
 
 
 
Figure  3.9: SDS-PAGE Gel (left) and corresponding Western Blot (right) of IN protein purification by nickel 
chelating column chromatography. This sample was eluted with 350mM imidazole. Protein molecular 
weight markers (in kDa; kilodalton) are indicated on the left. The arrow indicates the expressed and 
purified IN protein.  
INwt 
INwt 
30kDa 
7kDa 
175kDa 
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Figure  3.10: SDS-PAGE (left) and corresponding Western Blot (right) of IN protein purified by nickel 
chelating column chromatography. This sample was eluted with 500mM imidazole. Protein molecular 
weight markers (in kDa; kilodalton) are indicated on the left. The arrow indicates the expressed and 
purified IN protein.  
 
The recombinant soluble IN (INsol) was successfully purified, as confirmed by SDS-
PAGE (Figure 3.11). Because the recombinant INsol was purified on the AKTA system, 
analysis of different fractions (flow rate of 1.5ml/min) was possible. The bulk of 
protein eluted between fractions 23 to 60, with the majority detected in fractions 
24 and 25. Some contaminating proteins were detected in the early eluted fractions 
(Figure 3.11). However, INsol was detected as late as fraction 60 with little or no 
contamination visible on the gel. For this reason, fractions 23 to 30 and 31 to 60 
were pooled and analyzed separately.  
 
Quantification of the purified INwt and INsol showed the samples were concentrated 
to 559μg/ml and 740μg/ml, respectively as per results of the BCA assay, and using 
the Beer-Lamberts law: A=εlc. Where the extinction coefficient (ε) of IN is 
calculated at 50 460 M
-1
 cm
-1
 (Jenkins et al. 1996) at 280nm for IN, The Molar (M) 
concentrations were calculated for INwt and INsol to be 2μM and 6μM as per 
spectrophotometric results, respectively.  
 
INwt 
30kDa 
7kDa 
175kDa 
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Figure  3.11: SDS-PAGE analysis of the purification of INsol. The enzyme is clearly noticed in the 24
th
 and 
25
th
 fractions, however, contamination is noticed in these fractions. The protein eluted between fractions 
23 and 60. The arrow indicates the purified IN protein. 
 
3.4. Recombinant IN and INsol activity 
3.4.1. High throughput microtitre plate HIV-1 integration assay 
After several attempts and optimization of concentrations of donor DNA, Target DNA 
and IN, the high throughput microtitre plate HIV-1 integration assay was successfully set 
up.  
 
The purified INwt and INsol were both tested for functional activity in the high throughput 
microtitre plate HIV-1 integration assay. Activities of the INwt and INsol with a single 
concentration of Target DNA (150nM), as measured by fluorescence, are shown in 
Figure 3.12A. Results confirmed that INsol showed enzymatic activity (Figure 3.12A; 
yellow bar) compared to the blank control (p=0.0136), whereas the INwt showed little to 
no enzymatic activity (Figure 3.12A; red bar) compared to the blank control (p=0.1381), 
as compared to the background (Figure 3.12A; blue bar). Overall, INwt showed little to 
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no enzymatic activity, and was excluded from further assays. INsol can initiate strand 
transfer and was used in all subsequent experiments.  
 
A dose response curve of INsol to varying Target DNA concentrations is shown in Figure 
3.12B. INsol showed an increase in activity proportional to increasing Target DNA 
concentrations, reaching a plateau at high concentrations of Target DNA. These results 
serve to further confirm that INsol is functional. 
 
 
 
 
Figure  3.12 : HIV-1 recombinant integrase activity from the high throughput microtitre plate HIV-1 
integration assay, as measured in arbitrary fluorescence units (excitation 485nm and emission 535nm). A) 
Purified recombinant IN activity results using only a single Target DNA concentration (150nM). The blue, 
yellow and red bars indicate the fluorescence readings for the negative control (no-IN), test containing 1 
μM of INsol, and test containing 1μM of INwt, respectively, showing that INsol is active. All tests were done 
in duplicate. B) Dose response of INsol at different ranges of Target DNA concentrations. Results were 
normalized to a negative control containing no IN at maximum Target DNA concentration (270nM), and 
show that INsol activity increases as the Target DNA concentration increases. The curve has a R
2
 value of 
0.8629. All tests were done in duplicate. 
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The modifications to the high throughput microtitre plate HIV-1 integration assay 
protocol using INsol allowed for a more absolute quantification of substrate reactivity 
(Figure 3.13). Results obtained from the modified protocol were also more reproducible 
and showed a greater significant difference between the blank control and enzymatic 
test (p=≤ 0.0001) compared to the unmodified assay. 
‘ 
 
 
Figure  3.13: HIV-1 recombinant integrase activity from the modified high throughput microtitre plate HIV-
1 integration assay, as measured by absorbance (405nm). Results show a definitive difference between 
INsol and the blank control. Heights of the columns indicate an average mean of a triplicate. 
 
 
The modified protocol was used to test the chicoric acid control inhibitor (works 
similarly to Raltegravir in that it binds to the IN active site). Results confirmed that the 
assay can successfully be used to test IN inhibitors, since they showed a dose response 
curve: as the chicoric acid concentration increases, the recombinant IN activity 
decreases (Figure 3.14). The IC50 was calculated at 101.5nM of inhibitor. 
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Figure  3.14: HIV-1 recombinant integrase (IN) activity from the modified high throughput microtitre plate 
HIV-1 integration assay, as measured by absorbance (405nm) and normalized to a positive control (%). As 
the concentration of the chicoric acid inhibitor increases, the recombinant IN activity decreases. Points 
indicate average mean of a triplicate. IC50 is calculated as 101.5nM on GraphPad Prism 5.1. 
 
3.4.2. HIV-1 Integrase Urea-PAGE Based Functional Analysis  
Despite repeated attempts, the Urea-PAGE strand transfer assay was not successfully 
established.  
 
Figure 3.15 is a representative autoradiograph of the Urea-PAGE strand transfer assay. 
The Target DNA was 5’-radiolabelled on both the top and bottom strands.  
Radiolabelling of DNA worked, since Target DNA, as well as the control donor DNA was 
detected for all experiments. Because strand transfer can excise the Target DNA at any 
point to integrate the donor DNA, and a single Target DNA can accept more than one 
integration product from different donor stands, successful strand transfer detection on 
the autoradiograph would show ladder formation/pattern above and below the labelled 
Target DNA substrate. This was not evident on any developed autoradiographs, 
although in the experiment depicted in Figure 3.15, the donor DNA negative control 
(Figure 3.15; lane 4) gave a false positive result, and had the type of ladder pattern that 
is expected from ST activity.  
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Figure  3.15: Representative autoradiography of the Urea-Gel based assay using Assay Buffer 2. Labelled 
Target DNA and Donor (32 mer) DNA were mixed with INsol from purification A (lane 1), INsol from 
purification B (lane 2), or a no IN enzyme control (lane 3). Labelled Donor DNA only and labelled Target 
DNA only controls are shown in lanes 4 and 5, respectively.  
 
 
 
 
 
 
 
 
 
 
Figure  3.16: Representative autoradiography of the Urea-Gel based assay depicting use of Assay Buffer 1. 
Lanes are indicated. Labelled Target DNA and labelled Donor 1 (Table 2.2) DNA were mixed with INsol from 
purification A (lane 1), INsol from purification B (lane 2), or a no IN enzyme control (lane 3). Labelled Donor 
DNA only and labelled Target DNA only controls are shown in lanes 4 and 5, respectively. Donor DP (Table 
2.2) concentration was 60nM and target concentration was 100nM. 
 
? 
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The uppermost top bands detected in Figure 3.15 (labelled “?”) may be Target DNA-IN 
aggregates that have not entered the gel during electrophoresis. Similar results were 
experienced when using shorter donor substrates (Table 2.2, DP; Figure 3.16).  
 
3.4.3. SPA bead Strand Transfer Assay 
The SPA bead strand transfer assay proved more difficult to set up and optimize, as 
compared to the high throughput microtitre plate HIV-1 integration assay. The INsol was 
tested for functional activity in the SPA bead assay, and measured in counts per million 
(CPM; Figure 3.17). Preliminary results show CPM values obtained for the SPA beads 
complexed with INsol indicated a higher scintillation count as compared to the negative 
control containing no-IN enzyme. These results were, however, not reproducible. The 
control inhibitor, chicoric acid, was used in the SPA bead strand transfer assay. As the 
inhibitor concentrations increased the enzymatic activity decreased, indicated by a 
sigmoidal curve (Figure 3.18) fitted to readings taken in duplicate. The IC50 was 
calculated to be 248.5nM, but these results were not repeated in an independent 
experiment. 
 
 
Figure  3.17: SPA bead assay activity results. The bead assay results indicate that there is ST activity when 
comparing the INsol to the Blank control. 
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Figure  3.18: SPA bead assay with increasing inhibitor concentration. As the concentration of the chicoric 
acid inhibitor increases, the recombinant INsol activity decreases. Points indicate the average mean of a 
duplicate. IC50 is calculated as 248.5nM on GraphPad Prism 5.1. 
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CHAPTER 4 
Discussion 
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4. Discussion  
This study describes the successful establishment of an HIV-1 subtype C specific 
integrase genotyping assay and description of baseline mutations in integrase in HIV-1 
subtype C (and unique recombinant) infected integrase inhibitor-naive individuals in 
South Africa. In addition, recombinant IN was expressed and purified and tested in three 
strand transfer assays, of which the high throughput microtitre plate HIV-1 integration 
assay was optimized. 
 
RT-PCR and PCR amplification was successful for 91.3% of all samples, and included 51 
of the 58 patient plasma samples (not dependent on viral load), and all 22 proviral DNA 
samples, respectively. All 73 of the amplified samples were successfully sequenced. The 
integrase amplification and sequencing success rates are similar to those reported 
previously (Van Laethem et al. 2008; Eshleman et al. 2009; Van Baelen et al. 2009). 
Nucleotide sequences of the 73 newly characterized full-length integrase genes ranged 
from 867 to 876 base pairs, with intact open reading frames confirming the presence of 
functional integrase genes in all patients and primary virus isolates. The integrase 
intrasubtype nucleotide diversity for all 73 newly characterized samples varied between 
2.2% and 7.9%, similar to what has been reported previously (Rhee et al. 2008). 
 
As expected, the predominant circulating subtype within the South African population 
was HIV-1 subtype C (Figure 3.3), while the two samples (09ZAP35 and 09ZAP52) were 
unique AC and CG recombinants in integrase (Figure 3.4). Since subtype A predominates 
in East, Central and West Africa, and subtype G predominates in Central and West Africa 
it is possible these patients originated from these countries and a recombination event 
occurred in South Africa.   
 
The distribution of IN variants analyzed in Figure 3.5, showed that the newly 
characterized IN proteins varied from 288 to 292 amino acids in length, primarily due to 
the presence of an unusual tetrapeptide insertion (QNME) in the C terminus of 23 
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samples. This unusual insertion has been noted previously in two HIV-1 subtype C 
samples obtained from South Africa (Hunt et al. 2003; Tzitzivacos et al. 2009). The C-
terminus has been shown to be important for IN dimerization and DNA binding. This is 
believed to be crucial for proper function and positioning of the catalytic domain close 
to its target site (Michel et al. 2009). A CTD IN deletion mutant (terminal 15 amino acids) 
has been shown to be 80% catalytically impaired (Dar et al. 2009), therefore this 
extension may play an interesting role in IN catalytic function. This finding warrants 
further investigation to determine the impact of the insertion on the function of the 
integrase enzyme. It would be useful to obtain a recombinant IN protein with this 
extension and conduct functional assessments determining any differences in catalytic 
activity. This could be achieved by cloning a representative subtype C IN enzymes with 
this extension into a suitable vector, expressing, purifying and testing the functionality 
using the modified high throughput microtitre plate HIV-1 integration assay developed 
in this study. 
 
The sequences were analyzed for the presence of integrase mutations associated with 
reduced in vitro susceptibility to RAL (E92Q, F121Y, E138AK, G140AS, Y143RCH, S147G, 
Q148HRK, N155HS) and ELV (T66IAK, E92Q, F121Y, E138AK, G140AS, S147G, Q148HRK, 
S153Y, N155HS, R263K) (Stanford Database, updated 15 September, 2009). None of the 
samples contained the mutations associated with primary resistance (Y143RCH, 
Q148HRK and N155HS) (Figure 3.5).  
 
The E157Q mutation was observed among 4.1% (n=3) of patient samples, including two 
subtype C patient samples (09ZAP34 and 09ZAP53) and one recombinant (09ZAP52) 
patient sample (Figure 3.5). Until recently the E157Q mutation was listed among the 
mutations associated with reduced in vitro susceptibility to raltegravir and elvitegravir 
(http://hivdb.stanford.edu), but is now described as a minimally polymorphic mutation 
that is selected in vitro by elvitegravir and rarely in vivo by raltegravir, having minimal, if 
any effect on integrase inhibitor susceptibility. Interestingly, amongst several other 
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studies characterizing a total of 501 subtype C IN sequences, (Rhee et al. 2008; Van 
Laethem et al. 2008; Eshleman et al. 2009; Passaes et al. 2009) the E157Q mutation was 
only reported in one sample (1.4%) (Eshleman et al. 2009). 
 
The isoleucine at position 72 (I72) was identified at a high frequency amongst the 
subtype C samples and the 05ZAP52 recombinant (67.1%; n=49), whereas V72 and T72 
was found in 28.7% (n=21, including the 05ZAP35 recombinant) and 1.4% (n=1) of the 
patients, respectively, confirming that it is a naturally occurring subtype C polymorphism. 
This confirms the findings by Rhee et al.
 
(2008) who characterized naturally occurring 
variation in previously published HIV-1 group M integrase sequences, and found that 
390 of 432 (90.3%) integrase-inhibitor-naive subtype C samples analyzed contained 
isoleucine at position 72, and only 9.4% and 0.2% contained a valine and threonine, 
respectively. The polymorphic mutation, T97A, associated with integrase inhibitors was 
observed in one primary virus sample (05ZAFV27), while K156N, another accessory 
integrase inhibitor resistance mutation was found in patient 09ZAP34. The uncommon 
polymorphism K156N was not reported in subtype C, but occurs in 9% of subtype B and 
5% of subtype D sequences (Rhee et al. 2008). By contrast, T97A was observed in 
subtypes A, B, C, D and CRF01_AE and CRF02_AG, albeit at low frequencies (Rhee et al. 
2008). 
 
V201I has also been described as a resistance mutation that affects other earlier IN 
inhibitors (Rhee et al. 2008), however this mutation was not seen in any of the newly 
characterized patient samples. However, I201 is present in all 73 sequences, which 
indicates that HIV-1 subtype C is possibly predisposed to resistance to the earlier IN 
inhibitors such as S-1360. Similarly, the V165I, which was present in three samples 
(05ZAFV27, 05ZAP3 and 05ZAP54) is a resistance mutation possibly conferring resistance 
to the earlier IN inhibitors.  
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Because the antiretroviral drug history of the patient samples analyzed in 2009 was 
unknown, we could not address the influence of prior ARV therapy on integrase 
polymorphisms. Ceccherini-Silberstein (Ceccherini-Silberstein et al. 2007) reported 
several integrase polymorphisms, for example, M154I, V165I and M185L, that were 
positively associated with specific reverse transcriptase mutations (F227L and T215Y) in 
treated patients. In our study, the V165I polymorphism was noted in 3 samples, 09ZAP3, 
09ZAP54 (unknown drug history) and 05ZAFV29 (antiretroviral drug naive). This 
highlights the need for ongoing surveillance of integrase mutations, as well as HIV-1 
subtype C specific phenotypic studies to elucidate the relevance of the abovementioned 
polymorphisms (as well as naturally occurring polymorphisms) in the absence of the 
signature integrase mutations on susceptibility/resistance to integrase inhibitors.   
 
Overall, none of the three previously reported major mutations (Y143R/C/H, Q148H and 
N155H) associated with resistance to integrase inhibitors were observed in our cohort, 
indicating that integrase inhibitors may be used as a treatment option in South Africa. 
This genotyping assay is available and can be implemented if/when raltegravir becomes 
available in South Africa. 
 
Extensive IN sequence analysis from the 22 viral isolates led to the identification of 
suitable HIV-1 subtype C candidate viruses for PIC isolation and activity assays. The 
initial methodologies for HIV-1 infection and PIC isolations were identical to those 
described by (Brooun et al. 2001), with the exception of using a different viral isolate. 
Because isolate 05ZAFV3 was not capable of infecting CEM-SS cells, other cell lines were 
used in co-culture experiments. Isolation of PICs from SupT1/SupT1 and SupT1/MT-2 co-
culture experiments were perceived to be a failure by SDS-PAGE and Western blot 
analysis (results not shown). This may be attributed to lower concentrations of isolated 
PICs from the SupT1/SupT1 and SupT1/MT-2 co-culture experiments, or the suitability of 
Western blots as a detection method. In addition, the monoclonal antibody used was 
specific for the HXB2 strain of HIV-1 subtype B (Nilsen et al. 1996). Therefore, the 
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antibody may not have bound optimally to the subtype C IN enzyme present in the 
purified PICs.  
 
The published PIC isolation methods are all similar/identical, therefore future 
optimization studies should focus on using the same viral isolate (HXB2) used in the 
publication by (Brooun et al. 2001) as control. In addition, a more sensitive detection 
method such as the real time PCR assay and Southern blot analysis that detects 
integrated oligonucleotide products can be established (Engelman et al. 2008).  
 
Because our attempt to isolate HIV-1 subtype C PIC’s was unsuccessful, the study focus 
shifted to the isolation of recombinant IN enzymes, INwt and INsol for the establishment 
and use in strand transfer assays. Both proteins were successfully expressed and 
purified (Figures 3.9 to 3.11). Because several groups have shown that the soluble 
(Bushman et al. 1993; Hazuda et al. 1994; John et al. 2005) and insoluble (Bushman et al. 
1993) fractions of INwt are active, and sufficient yields of INwt were obtained from the 
soluble fraction in this study, the insoluble aggregates were not refolded. The Bushman 
et al. (1993) and John et al. (2005) groups used the same expression plasmid (pINSD.His) 
as the one used in this study, and showed that the purified soluble IN fraction had 
enzymatic activity in gel-based assays and microtitre plate assays. In addition, the 
purification of the soluble fraction of the INwt enzyme employed in this study was similar 
to the methods described by Bushman et al. (1993) and John et al. (2005), with the 
exception of centrifugation speeds and thrombin cleavage of the His-tag. The INsol 
(double mutant) was purified under native conditions as described previously (with the 
exception of the His-tag cleavage), where it was shown to have catalytic activity similar 
to that of INwt enzyme (Jenkins et al. 1995; Jenkins et al. 1996). The F185K and the 
C280S mutations of INsol increase the enzyme’s solubility when expressed in bacterial 
cells, and allow for easier handling when purifying and concentrating the recombinant 
enzyme.  
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The recombinant INwt and INsol proteins in this study were expressed with an N-terminal 
His-tag, and there was no thrombin cleavage step to remove the His-tag. Bushman et al. 
(1993) removed the His-tag from their purified INwt protein, whereas John et al. (2005) 
did not. This implies that removal of the His-tag does not impact on the INwt or INsol 
enzymatic function. Furthermore, His-tag removal from INsol and a subtype C IN (cloned 
from pINDIE-C1) was shown to be unnecessary and does not impact on IN activity (Bar-
Magen et al. 2009).  
 
There are two major published assays (with numerous modifications) that utilize 
recombinant IN enzymes to monitor ST activity (Chow 1997; Andrake et al. 2009). These 
being the gel-based assays and high throughput solid support assays. Three assays 
which cover the range of the available assays were selected to be set-up and optimized 
in this study. These included the high throughput microtitre plate HIV-1 integration 
assay (Hazuda et al. 1994; Vink et al. 1994), HIV-1 Integrase Urea-PAGE Based Functional 
Analysis (Bushman and Craigie 1991; Jenkins et al. 1996) and the SPA bead ST assay 
(Grobler et al. 2009). 
 
The rationale behind the high throughput microtitre plate HIV-1 integration assay 
utilizes oligonucleotides that mimic the U5 LTR region of HIV-1 (Bushman and Craigie 
1991) and is known as the Donor DNA, which is biotinylated at the 5’-end (Table 2.2). 
The Donor DNA is designed to be preprocessed (Bar-Magen et al. 2009), therefore, the 
assay does not test 3’-P and only specifically tests ST activity. During the assay, the IN 
dimer assembles and is stabilized on the donor substrate (Ellison and Brown 1994). The 
Target DNA is then added, and the assembled IN/Donor then nicks the target at a non-
specified location, but prefers GC rich areas (Hazuda et al. 1994). IN also has nonspecific 
nuclease activity (Engelman and Craigie 1995) and therefore the Target DNA has a FITC 
label on both 3’-ends of the double stranded oligonucleotide so as not to lose the signal. 
After the Target DNA is ligated into the Donor DNA, the IN is washed off and only the 
strand transfer products remain in the well. Fluorescence can thereafter be measured to 
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detect ST activity, or as in the case of the modified protocol, an HRP-conjugated 
antibody against FITC could be used with subsequent detection via absorbance of the 
HRP substrate. 
 
The high throughput microtitre plate HIV-1 integration assay and a modification thereof, 
was set up according to published methods (Hazuda et al. 1994; Chow 1997), with 
several exceptions. The experimental differences of the present study with published 
work included different assay conditions and the oligonucleotide sequences used. The 
assay conditions used in this study included two different buffers tested, i.e. Assay 
Buffer 1 and Assay Buffer 2 (see section 2.6.). Assay Buffer 1 was shown to allow for 
better IN activity in the high throughput microtitre plate HIV-1 integration assay, as 
compared to Assay Buffer 2 (data not shown). These buffers were chosen based on 
magnesium efficiency (Engelman and Craigie 1995) and previously published protocols 
(Hazuda et al. 1994; Jenkins et al. 1996; Bar-Magen et al. 2009). Comparison of the 
conditions for activity assays of published work showed that the maintenance of a pH 
between 6.5 and 7.5 is important (John et al. 2005) for IN enzymatic activity in vitro, 
where Good’s buffers (Good et al. 1966) with pKa values close to these pH ranges are 
ideal. The ionic strength plays a role in activity depending on the metal ions present, and 
should not exceed 100mM NaCl. Addition of a mild reducing agent such as DTT or β-
mercaptoethanol is essential to maintain the solubility of the IN enzyme. The critical 
components required for strand transfer are the metal ions such as MgCl2 or MnCl2 
which interact with the active site of the IN enzyme. Glycerol and ZnCl2 were also shown 
to enhance activity (Engelman and Craigie 1995; Zheng et al. 1996) and these were also 
included in the buffers used in this study (See section 2.6 and Table S6.1). In addition, 
DMSO, PEG and Nonidet-P40 (now known as Igepal) are also commonly used reagents in 
buffers (Jenkins et al. 1996), and save for Nonidet-P40 the prior two components were 
used in Assay Buffer 2. Although the compositions of buffers seem to vary between 
published methods, the abovementioned principles were adhered to in the present 
study. Besides the buffer conditions, the oligonucleotide donor substrates used in this 
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study were longer (32 mer) than commonly used (21 mer) substrates. However, the 
longer substrates are still a mimic of the U5 LTR sequence that IN is specific for, and 
oligonucleotide donor substrates of up to 35 mer have been used in activity assays 
before and shown to improve concerted integration (Hazuda et al. 1994; Engelman and 
Craigie 1995; Chow 1997; Andrake et al. 2009; Bar-Magen et al. 2009).  
 
Results from the high throughput microtitre plate HIV-1 integration assay using INwt and 
INsol purified during the course of this study, showed differing results for the INwt, but 
similar results for the INsol (Hazuda et al. 1994; John et al. 2005; Bar-Magen et al. 2009).  
The enzymatic activity of the soluble fraction of INwt could not be reproduced in this 
study (Figure 3.12). Because the expressed/purified recombinant INwt protein was the 
correct size (Figures 3.9 and 3.10), the lack of enzymatic activity could most likely be 
attributed to incorrect folding of the protein. The addition of reducing agents such as 
DTT or β-mercaptoethanol in the assay buffers (see sections 2.6.1 - 2.6.2) helps to limit 
aggregation. However, it is possible that the concentration of the purified recombinant 
INwt protein was far too high, causing it to aggregate. These aggregates were noticed 
during concentration with the size exclusion columns (section 2.5.). The subsequent 
dialysis with a buffer containing DTT or β-mercaptoethanol may not have been sufficient 
to maintain the solubility of the protein. Future purification procedures may require a 
reducing agent to be present throughout the purification. 
 
By contrast, the purified INsol showed about a two-fold activity over a negative blank 
(Figure 3.12A) and about a ten-fold activity over the negative in the modified protocol 
(Figure 3.13). In addition, activity of the enzyme showed a dose dependency curve with 
increasing concentrations of Target DNA, where these results indicate that the IN 
enzyme begins to get saturated with target and only a limited amount of substrate is 
integrated (Figure 3.12A). These results are similar to those reported previously (Hazuda 
et al. 1994; John et al. 2005; Wang et al. 2005). Where Hazuda et al. (1994) showed a 
hyperbolic curve of activity with increasing concentration of Target DNA. Wang et al. 
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(2005) showed a two-fold increase in activity after one hour over a control using a 
similar method to the high throughput microtitre plate HIV-1 integration assay used in 
this study. John et al. (2005) showed, under similar conditions to the modification of the 
high throughput microtitre plate HIV-1 integration assay used in this study, close to a 10 
fold increase in activity. Chicoric acid is an inhibitor of ST that binds to the active site of 
IN (Reinke et al. 2002). Increasing concentrations of chicoric acid in the high throughput 
microtitre plate HIV-1 integration assay confirmed that the assay can be used for the 
rapid screening of potential HIV-1 IN inhibitors (see Figure 3.14). The IC50 of 101.5nM 
obtained here is similar to previously published data ranging from 100nM – 500nM 
(Charvat et al. 2006).  
 
Because the high throughput microtitre plate HIV-1 integration assay is an indirect 
measure of IN activity, the purified recombinant INsol was then tested in a urea gel assay 
which allows for the visualization of ST products, and is thus a more direct indication of 
INsol enzymatic activity. Despite repeated attempts (see section 3.5 and supplementary 
data), it was not possible to successfully set up the assay. The assay conditions were 
similar to published assays that have shown good activity with the same purified INsol 
protein used in this study (Jenkins et al. 1996; Bar-Magen et al. 2009). The current assay 
conditions included long Donor substrates (Figure 3.15, 32 mer) and short Donor 
substrates (Figure 3.16, 21 mer). Further parameters that were changed in an attempt 
to optimize the assay included using a range of buffers, and different concentrations of 
substrates and enzyme as indicated in the supplementary section (Figures S1-S5 and 
SupTable 5.1). Of interest, most of the analyzed radiographs contained strong signals in 
the wells of each gel. This obstruction may be attributed to oligomers alone, or a 
complex of oligomers and IN that could not enter the gel.  
 
Most published methods use oligomers that are PAGE gel purified (Bar-Magen et al. 
2009), however, this was not carried out in this study. Future attempts should include 
the use of PAGE gel purified oligomers. Unincorporated 
32
P-ATP is usually removed from 
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the substrates before use (Jenkins et al. 1996; Bar-Magen et al. 2009). This was carried 
out, but the removal of unincorporated 
32
P-ATP greatly reduced the radioactive signal. 
After removal of unincorporated 
32
P-ATPs, intensifying screens 200 (Carl Roth) were 
used to increase the sensitivity (Figures S2, S3 and S5). Intensifying screens have also 
been mentioned to increase sensitivity of detection during exposure of the X-ray films 
(Walker et al. 2008). However, the radioactive signal only increased marginally. Most 
published papers use a phosphorimager for detection of ST products (Jenkins et al. 1996; 
Bar-Magen et al. 2009). The phosphorimager is more sensitive due to having a more 
linear detection and a higher cut-off compared to X-ray film and may also be used for 
quantification (http://www.downstate.edu/biochemistry/phosphor_lab.html). In 
addition, pre-flashing the X-ray film with a short burst of low energy light also increases 
the linear range of the X-ray film and may increase the sensitivity. Future 
recommendations would include the use of pre-flashed X-ray film or a phosphorimager 
to enhance the sensitivity of detection in the assay. 
 
A further modification to the microplate assay is the SPA bead assay which was set up 
using the purified recombinant INsol according to specifications from the literature 
(Grobler et al. 2009). This assay measures the direct binding of Target DNA to the 
immobilized donor DNA. The rationale behind this assay utilizes the scintillation 
properties of the SPA beads and activation of this scintillation when they are in close 
contact with a radioactive source. The radiolabel on the Target DNA substrate when it is 
in solution would not induce scintillation as strongly compared to if it were attached to 
the beads. Therefore, kinetic binding properties of the Target DNA to Donor DNA could 
be further elucidated using this assay. Results show levels of INsol activity and inhibition 
comparable to those showed by Grobler et al. (2009) with the IC50 value of 248.5nM for 
chicoric acid inhibition within the published range of 100nM – 500nM mentioned above 
(Charvat et al. 2006). These results are preliminary, however, and require further 
verification before its usage can be made routine. Another modification could be done 
using magnetic beads as a platform to immobilize donor DNA (Albanese et al. 2008). 
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These modifications all aid in the efficiency of the assay, and show the versatility of the 
application.  
 
Overall, this study describes the establishment of a high throughput microtitre plate 
HIV-1 integration assay that can be used to screen for novel IN inhibitors developed in 
South Africa. In addition, a genotyping assay to screen for the emergence of IN 
mutations as a result of IN inhibitor use was successfully set up, and can be 
implemented by the genotyping laboratory when IN inhibitors become available in the 
public sector. While the high throughput microtitre plate HIV-1 integration assay was 
successfully set up and used to screen for chicoric acid inhibitor activity, the SPA bead 
strand transfer assay, once validated, can replace the microtitre plate HIV-1 integration 
assay since it has higher throughput capabilities required to screen chemical libraries.  
 
Future work should focus on the optimization of the Urea-PAGE strand transfer assay. 
This assay needs to be optimized in order to confirm that each batch of purified 
recombinant IN has ST activity prior to its inclusion in screening assays such as the high 
throughput microtitre plate HIV-1 integration assay or SPA bead strand transfer assay. 
Lastly, future efforts in isolation of an HIV-1 subtype C recombinant IN for use in these 
assays may allow for the screening and identification of a locally relevant IN inhibitor.    
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6. Supplementary 
Table S6.1: Buffer recipes used in Urea-PAGE based assays 
Name Recipe 
Assay Buffer 1 20mM HEPES pH 7.3, 75mM NaCl, 10 mM MgCl2, 2 µM ZnCl2, 1 % 
glycerol 
Assay Buffer 2 25mM HEPES pH 7.5, 10mM MgCl2, 5mM DTT, 10% PEG 8000, 10% 
DMSO, 20μM ZnCl2, 75mM NaCl 
Assay Buffer 3 20 mM HEPES pH 7.5, 30 mM NaCl, 1mM DTT, 125 µM ZnCl2, 7.5 mM 
MnCl2 
Assay Buffer 4 50 mM MOPS pH 7.2, 10 mM MgCl2, 14 mM B-ME 
 
 
 
 
 
 
 
 
 
 
Figure S1: Autoradiograph of Urea PAGE based strand transfer activity assay using Buffer 3. Lanes 1-4 are 
no enzyme controls. Lanes 5-8 are enzymatic tests. All wells contained Target where only the target (T1 
and T2) were radiolabeled. Order of donor additions are 1: DU/B1, 2: DP/B1, 3:DU/B2, 4:DP/B2 (same 
order for 5-8). Buffer 3 was used for the reactions. Donor (21 mer) concentration was 200 nM target 
concentration was 400 nM and enzyme concentration was 1 μM. Only target was radiolabelled 
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Figure S2: Autoradiograph of Gel based strand transfer activity assay depicting use of SPA Beads as 
substrate immobilizer. Lanes are indicated. All wells contained Target where only the target (T1 and T2) 
were radiolabeled. Donor (32 mer) concentration was 360 nM target concentration was 2 μM and enzyme 
concentration was 0.5 μM. Only target was radiolabelled. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3: Autoradiograph of Gel based strand transfer activity assay utilizing buffer 4. Lanes are indicated. 
Donor concentration was 125 nM target concentration was 750 μM and enzyme concentration was 1 μM. 
Target and donor was radiolabelled. DU denotes unprocessed donor, DP denotes processed donor and T 
denotes target. 
IN- IN+ IN- IN+ 
Before removal 
of beads 
After removal of 
beads 
IN- 
Possible ST 
smear 
T DU DP DU DP 
IN + target Only donor 
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Figure S4: Results depicting use of buffer 1. Donor concentration was 60 nM and target concentration was 
100 nM and enzyme concentration was 1 μM. UnT denotes non radiolabeled Target DNA. T denotes 
labelled target. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5: Results depicting use of buffer 3. Donor DNA was 500 nM and Target DNA was 2 µM and 
enzyme was 2 μM. 
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SEQUENCE NOTES
Natural Polymorphisms of integrase
Among HIV Type 1-Infected South African Patients
Muhammad Q. Fish,1 Raymond Hewer,2 Carole L. Wallis,1 Willem D.F. Venter,3
Wendy S. Stevens,1 and Maria A. Papathanasopoulos1
Abstract
An HIV-1 subtype C specific assay was established for integrase genotyping from 51 integrase inhibitor-naive
patient plasma samples and 22 antiretroviral drug-naive primary viral isolates from South Africa. Seventy-one of
the 73 samples were classified as HIV-1 subtype C and two samples were unique AC and CG recombinants in
integrase. Amino acid sequence analysis revealed there were no primary mutations (Y143R=C=H, Q148H=R=K,
and N155H=S) associated with reduced susceptibility to the integrase inhibitors raltegravir and elvitegravir.
However, one sample had the T97A mutation, three samples had the E157Q and V165I mutations, and the
majority of samples contained the polymorphic mutation V72I. The expected finding of no major integrase
mutations conferring resistance to integrase inhibitors suggests that this new antiretroviral drug class will be
effective in our region where HIV-1 subtype C predominates. However, the impact of E157Q and other naturally
occurring polymorphisms warrants further phenotypic investigation.
TheHIV-1 integrase enzyme (32 kDa, 288 amino acids) isresponsible for the irreversible integration of the newly
synthesized viral cDNA into the host cell chromosomal DNA,
an essential step in the HIV-1 replication cycle.1 Integrase is
composed of three functional domains: the N-terminal do-
main (amino acids 1–50), which coordinates zinc binding, the
catalytic core domain (amino acids 51–212), which contains
three catalytic residues forming a DDE motif, and the C-
terminal domain (amino acids 213–288), which is involved in
host DNA binding and integrase oligomerization.2
Integrase functions in cells within the context of high-
molecular-weight preintegration complexes that are formed
in the cytoplasm after reverse transcription of the viral RNA.
HIV-1 integration is subdivided into two steps with distinct
kinetics and requirements. In the cytoplasm, a dinucleotide
adjacent to a phylogenetically conserved CA is hydrolytically
cleaved off the 30 end of each strand of the linear viral cDNA
by integrase in the preintegration complex (30-processing).3–7
After nuclear transport of the preintegration complex, two
phosphodiester bonds on each strand of the chromosomal
DNA are targeted by the 30-hydroxyls at the ends of the viral
DNA, resulting in its insertion within the host genome (strand
transfer).3–7 Removal of the two unpaired nucleotides on the
50 viral DNA ends and gap filling of the interfaces between the
viral and host genomic DNA are then done using host DNA
repair machinery via mechanisms that are not yet fully un-
derstood. Completion of integration results in a fully func-
tional provirus, which can then be used to initiate viral DNA
transcription. There is no known human homologue to in-
tegrase, thus making it an ideal antiretroviral drug target.
Raltegravir (Isentress, Merck & Co., Inc., Whitehouse Sta-
tion, NJ), the first integrase inhibitor to be approved by
the U.S. Food and Drug Administration (October 2007), has
successfully been used in combination with other anti-
retroviral drugs for treatment-experienced HIV-1 patients
with multidrug-resistant strains. Raltegravir blocks viral
replication by inhibiting DNA strand transfer.8 However,
drug resistance to integrase inhibitors has been shown to
occur both in vivo and in vitro, and is the consequence of
mutations that are selected in the viral integrase gene targeted
by the strand transfer antiretroviral drugs such as raltegravir
and elvitegravir (Gilead Sciences, Foster City, CA). To date,
there are at least 30 substitutions that have been specifically
associated with the development of resistance to raltegravir
and=or elvitegravir (http:==hivdb.stanford.edu). However,
the main mutational pathways associated with raltegravir
and elvitegravir resistance include signature mutations at
integrase positions 143, 148, and 155.
Access to antiretroviral drugs has escalated dramatically in
the sub-Saharan African region in the past decade. Regimens
1HIV Pathogenesis Research Laboratory, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical
School, Parktown, Johannesburg, South Africa.
2AuTEK Biomed, Mintek, Private Bag X3015, Randburg, Johannesburg, South Africa.
3Reproductive Health and HIV Research Unit, University of the Witwatersrand Medical School, Parktown, Johannesburg, South Africa.
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in this region almost universally place a thymidine analogue
with lamivudine and a nonnucleoside reverse transcriptase
inhibitor as first line therapy, with a protease inhibitor-based
regimen for those failing first line therapies. However, these
regimens carry significant toxicities, requiring drug substitu-
tions. In addition, an increasing number of patients require
alternative regimens as they fail first and second line regimens
due to nonadherence, toxicity, or the development of drug
resistance. Thus, the effectiveness of integrase inhibitors such
as raltegravir needs to be investigated as alternative anti-
retroviral drug treatment options are required. Several groups
have published genotypic assays for the amplification and
sequencing of integrase from diverse HIV-1 group M sub-
types,9–11 however, we opted to establish a subtype C-specific
integrase genotyping assay. This study describes the baseline
mutations in integrase in HIV-1 subtype C (and unique re-
combinant) infected integrase inhibitor-naive individuals in
South Africa.
A total of 80 samples from patients attending the Charlotte
Maxeke Johannesburg Hospital were available for purposes
of this study. These included 58 randomly selected patient
plasma samples sent for routine viral load monitoring during
2009, and 22 well-characterized primary HIV-1 isolates from
antiretroviral drug-naive AIDS patients isolated during
2005.12 The patients viral loads ranged from 1500 to >3 mil-
lion RNA copies=ml, and included antiretroviral drug-naive
and treatment-experienced patients. Ethical clearance for the
study was obtained for Research on Human Subjects (Medi-
cal) at the University of theWitwatersrand (clearance number
M090575). Viral RNA was extracted from the 58 patient
plasma samples using the automated Roche MagNa Pure LC
analyzer and theMagNa Pure LC Total Nucleic Acid Isolation
kit (Roche, Germany), according to the manufacturer’s in-
structions. Proviral DNA from the 22 viral isolates was ex-
tracted from p24 antigen-positive cultures with a High Pure
PCR Template Preparation kit (Roche, GmbH, Germany) ac-
cording to the manufacturer’s instructions. The full-length
integrase gene was reverse transcriptase polymerase chain
reaction (RT-PCR) amplified into cDNA from the extracted
viral RNA samples using the reverse primer SQ9RC(3) (50-
TTGGATGTCTGCTTTCATAATGAT-30)13 and the Expand
Reverse Transcriptase (RT) kit (Roche Diagnostics, Germany),
as per the manufacturer’s instructions. Amplification from
synthesized cDNA or extracted proviral DNAwas performed
using primers SQ7F(2) (50-AGGAGCAGAAACTTTCT
ATGTAGATGG-30)13 and SQ9RC(3) with the Expand High
FidelityPLUSkit (Roche, Germany), as per the manufacturer’s
instructions. PCR amplicons (approximately 1.3 kb in length)
were purified using the High Pure PCR Product Purification
kit (Roche), as per the manufacturer’s instructions.
Primers spanning the full-length integrase (*880 bp) were
used to sequence the PCR products in both directions
(population-based sequencing). These included QFIN1F (50-
ATGGGTACCAGCACACAAAG-30), QFIN2F (50-TAGC
AGGAAGATGGCCAGTC-30), QFIN1R (50-CTCTCCTTG
AAATATACATATGGTGC-30), and QFIN2R (50-CTACTA
CTCCTTGACTTTGGGG-30). Purified amplicons were se-
quenced with the ABI Big Dye terminator system (v3.1) ac-
cording to the manufacturer’s instructions on the ABI Prism
3730 and 3100-Avant Genetic Analyzer (Applied Biosystems,
Foster City, CA). Sequence data were edited using the
Sequencing Analysis V3.3 program (Applied Biosystems),
and the complete integrase sequences were assembled and
manually edited using Sequencher V4.7 (Genecodes, Ann
Arbor, MI). For subtyping, a multiple alignment of the full
length integrase regionwith references fromHIV-1 subtypes A
to K, CRF01_AE, and CRF02_AG (http:==hiv-web.lanl.gov)
was generated in Clustal X. Aligned sequenceswere converted
toMEGAV3.0 format and used in phylogenetic andmolecular
evolutionary analyses. A phylogeny reconstruction of each
integrase gene was performed by neighbor-joining using the
Kimura two-parameter distance matrix. The stability of the
nodes was assessed by bootstrap analysis (1000 replicates) and
bootstrap values >70% were considered significant. Nucleo-
tide sequences were converted to amino acid sequences and
compared to the 2004 consensus C sequence available from the
Los Alamos website (http:==hiv-web.lanl.gov). The amino acid
sequence alignment was extensively analyzed for the presence
of primary mutations, nonpolymorphic and polymorphic
mutations associated with resistance to known integrase in-
hibitors (http:==hivdb.stanford.edu).
RT-PCR and PCR amplification was successful for 91.3% of
all samples, and included 51 of the 58 patient plasma samples
(not dependent on viral load) and all 22 proviral DNA sam-
ples, respectively. All 73 of the amplified samples were
successfully sequenced. The integrase amplification and se-
quencing success rates are similar to those reported previ-
ously.9–11 Nucleotide sequences of the 73 newly characterized
full-length integrase genes ranged from 867 to 876 base pairs,
with intact open reading frames confirming the presence of
functional integrase genes in all patients and primary virus
isolates. The integrase intrasubtype nucleotide diversity for all
73 newly characterized samples varied between 2.2% and
7.9%, similar to what has been reported previously.14 Phy-
logenetic analysis of the full-length integrase nucleotide se-
quences, together with viruses from the major subtypes,
revealed that 71 sequences clustered within HIV-1 subtype
C with a bootstrap value of 100%, whereas two samples
(09ZAP35 and 09ZAP52) showed evidence of recombination
(Fig. 1). These two sequences were further analyzed using the
RIP 3.0 Program (http:==hiv-web.lanl.gov), which showed
that samples 09ZAP35 and 09ZAP52 were unique AC and CG
recombinants in integrase (results not shown). Since subtype A
predominates in East, Central, and West Africa, and subtype
G predominates in Central and West Africa, it is possible that
these patients originated from these countries and a recom-
bination event occurred in South Africa.
An alignment of the 73 integrase amino acid sequences was
extensively analyzed and compared, and a distribution of the
variants is shown in Fig. 2. The proteins varied from 288 to 292
amino acids in length, primarily due to the presence of an un-
usual tetrapeptide insertion (QNME) in the C terminus of the
protein in 23 patient and primary virus isolate samples. This
unusual insertion has been noted previously.15,16 The C ter-
minus has been shown to be important for integrase dimer-
ization and DNA binding. This is crucial for proper function
and positioning of the catalytic domain close to its target site.
This finding warrants further investigation to determine the
impact of the insertion on the function of the integrase enzyme.
The sequences were analyzed for the presence of integrase
mutations associated with reduced in vitro susceptibility to
raltegravir (E92Q, F121Y, E138AK, G140AS, Y143RCH,
S147G, Q148HRK, N155HS) and elvitegravir (T66IAK, E92Q,
F121Y, E138AK, G140AS, S147G, Q148HRK, S153Y, N155HS,
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FIG. 1. Phylogenetic relationships of the 73 newly characterized full-length integrase sequences with HIV-1 subtype refer-
ence sequences from the Los Alamos database (http:==hiv-web.lanl.gov). The unique recombinant sequences are boxed.
Phylogenetic trees were constructed from nucleotide sequence alignments, using neighbor joining and the Kimura two-
parameter distance matrix. The reliability of the branching order was estimated from 1000 bootstrap replicates, and only
bootstrap values of 70% or higher are shown.
R263K) (Stanford Database, updated 15 September, 2009).
None of the samples contained the mutations associated with
primary resistance (Y143RCH, Q148HRK, and N155HS).
The E157Q mutation was observed among 4.1% (n¼ 3) of
patient samples, including two subtype C patient samples
(09ZAP34 and 09ZAP53) and one recombinant (09ZAP52)
patient sample (Fig. 2). Until recently the E157Qmutationwas
listed among the mutations associated with reduced in vitro
susceptibility to raltegravir and elvitegravir (http:==hivdb.
stanford.edu), but is now described as a minimally poly-
morphic mutation that is selected in vitro by elvitegravir and
rarely in vivo by raltegravir, having a minimal, if any effect on
integrase inhibitor susceptibility. Interestingly, among several
other studies characterizing a total of 501 subtype C integrase
sequences,9,11,14,17 the E157Q mutation was reported in only
one sample (1.4%).11
The isoleucine at position 72 (I72) was identified at a high
frequency among the subtype C samples and the 05ZAP52
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FIG. 2. Distribution of variants among the 73 newly characterized full-length integrase sequences. The 2002 consensus
subtype C sequence (http:==hiv-web.lanl.gov) is shown at the top of each 30 amino acid sequence section. Numbers below the
consensus sequence indicate the number of annotated sequences (out of 73) containing an unambiguous amino acid at that
position. Beneath that are the amino acid variants with superscript numbers indicating the amount of times they occur.
Integrase functional domains and important residues are highlighted. The N terminal domain is highlighted in yellow, the
catalytic core domain in white, and the C terminal domain in blue; the catalytic triad (DDE) residues are in red and relevant
integrase inhibitor resistance mutations are in green.
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recombinant (67.1%; n¼ 49), whereas V72 and T72were found
in 28.7% (n¼ 21, including the 05ZAP35 recombinant) and
1.4% (n¼ 1) of the patients, respectively, confirming their
status as a naturally occurring subtype C polymorphism. This
confirms the findings by Rhee et al.14 who characterized nat-
urally occurring variation in previously published HIV-1
group M integrase sequences, and found that 390 of 432
(90.3%) integrase-inhibitor-naive subtype C samples analyzed
contained isoleucine at position 72, and only 9.4% and 0.2%
contained a valine and threonine, respectively. The polymor-
phic mutation, T97A, associated with integrase inhibitors was
observed in one primary virus sample (05ZAFV27), whereas
K156N, another accessory integrase inhibitor resistance mu-
tation, was found in patient 09ZAP34. The uncommon poly-
morphismK156Nwas not reported in subtype C, but occurs in
9% of subtype B and 5% of subtype D sequences.14 By contrast,
T97Awas observed in subtypesA, B, C,D, andCRF01_AEand
CRF02_AG, albeit at low frequencies.14
Because the antiretroviral drug history of the patient sam-
ples analyzed in 2009was unknown,we could not address the
influence of prior antiretroviral therapy on integrase poly-
morphisms. Ceccherini-Silberstein et al.18 reported several
integrase polymorphisms, for example, M154I, V165I, and
M185L, that were positively associated with specific reverse
transcriptase mutations (F227L and T215Y) in treated pa-
tients. In our study, the V165I polymorphism was noted in
three samples, 09ZAP3, 09ZAP54 (unknown drug history),
and 05ZAFV29 (antiretroviral drug naive). This highlights the
need for ongoing surveillance of integrase mutations as well
as HIV-1 subtype C-specific phenotypic studies to elucidate
the relevance of the above-mentioned polymorphisms (as
well as naturally occurring polymorphisms) in the absence of
the signature integrase mutations on susceptibility=resistance
to integrase inhibitors.
In conclusion, none of the three previously reported major
mutations (Y143R=C=H, Q148H, and N155H) associated with
resistance to integrase inhibitors was observed in our cohort,
indicating that integrase inhibitorsmay be used as a treatment
option in South Africa.
Sequence Data
The 73 integrase sequenceswere submitted toGenBankusing
Sequin V5.35 (http:==www.ncbi.nlm.nih.gov), and are avail-
able under the accession numbers GQ872465 to GQ872538.
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